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The Na+/H+ Exchanger 1 (NHE1), a membrane antiporter, has been implicated 
in tumour cell survival. However, the regulation of NHE1 expression level in 
tumour cells is not completely understood. Interestingly, the upregulation of 
NHE1 protein expression in PTEN-null Mouse embryonic fibroblasts 
(MEFPTEN-/-) compared to PTEN-wildtype Mouse embryonic fibroblasts 
(MEFPTEN+/+) does not correlate with an increase in NHE1 transcription. 
Hence, we hypothesized that increased NHE1 expression may be due to 
increased stability of the protein.  
  
In the current study, we show that Heat shock protein 90 (Hsp90) confers 
stability to NHE1 though enhanced interaction in MEFPTEN-/- cells as compared 
to MEFPTEN+/+ cells. The inhibition of Hsp90 activity using Geldanamycin and 
silencing of Hsp90 gene induced a decrease in NHE1 protein level in 
MEFPTEN-/- cells while no effect was observed in control cells. In addition, 
NHE1 was found to interact with Akt in MEFPTEN-/- cells. Both inhibition of Akt 
activation and silencing Akt gene expression decreased NHE1 protein 
expression. Moreover, our data reveals that Akt is involved in trafficking 
Hsp90 from the cytosol to the plasma membrane in MEFPTEN-/- cells. Similar 
result was observed in MCF10CA1a, a breast carcinoma cancer cell line.  
 
Additionally, we found that NHE1 may be involved in the regulation of Akt 
Serine 473 phosphorylation. We show that this occurs through the complex 
formation between NHE1, mTOR, Rictor in both MEFPTEN-/- and MCF10CA1a 
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cells. Taken together, this study establishes a possible tripartite complex 
between NHE1, Akt and Hsp90 that may be critical for stabilizing NHE1 
expression level and its role in survival of tumour cells. We propose that our 
findings might be critical for the development and maintenance of tumour 
cells. Indeed, results from this study could establish a new strategy to 
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CHAPTER 1: INTRODUCTION 
 
1.1 Na+/H+ exchanger-1 (NHE1) 
 
1.1.1 NHE1 isoforms and NHE1 structure   
 
The regulation of intracellular pH (pHi) is a tightly regulated parameter that has 
been shown to be instrumental for many cellular processes to occur1. 
Previous studies have shown that the Na+/H+ exchangers (NHE) are 
expressed on the cell membrane of various cell types and are thought to 
prevent variation of pHi in a cell that can result in changes that can affect the 
function of proteins, ion channels and other biological processes2.  
 
The discovery of NHE was first detected due to sodium-dependent pH 
regulation in bacteria3,4.  Over time, nine isoforms of the NHE family, NHE1 to 
NHE9, have been cloned and classified according to their tissue and cellular 
localization5. NHE1 is an ubiquitiously expressed member of the family while 
expression of NHE2-NHE9 isoforms appears to be more tissue specific6 
(summarized in Table 1). While NHE1 and NHE5 are enriched in the plasma 
membrane, NHE3 and NHE5 have also been detected in endosomal pools7-10. 
The NHE2-NHE4 isoforms are also thought to be more tissue specific, thus, 
detected in the kidney and gastrointestinal tract11-13. On the other hand, NHE6 
to NHE9 isoforms have been reported to exist in intracellular organelle 
membranes such as trans-golgi network, endosomes and mitochondria14,15. 
Importantly, members of the mammalian NHE family have been shown to be 
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involved in regulating significant physiological processes which also correlates 
with its localization within the cell16.  
 
 
Table 1. Summary of studies indicating tissue distribution and 
intracellular localization of NHE isoforms.  
 
NHE1 is a plasma membrane protein that is expressed in two forms; 
glycosylated mature protein with a molecular weight of 100–110 kDa and the 
unglycosylated immature protein that is detected at 90–91 kDa17. There are 
two functional domains that exist within NHE1, the N-terminal transmembrane 
segment which mediates the Na+/H+ exchange and the C-terminal regulatory 
cytoplasmic tail that is thought to associate with a myriad of signalling proteins 




NHE1 Plasma membrane; basolateral 
surface of epithelia 
 
Sardet  et al., 1989 
Orlowski et al., 1992 
Cavet et al., 2001 
NHE2 Plasma membrane; apical 
surface of epithelia 
 
Tse et al., 1993 
Cavet et al., 2001 
Malakooti et al., 1999 
NHE3 Plasma membrane; apical 
surface of epithelia  
Endosomal pools 
Amemiya et al., 1995 
Noel et al., 1996 
Akhter et al., 2002 
D'Souza Set al., 1998 
Tse et al., 1992 
Janecki et al., 1998 
NHE4 Basolateral membrane of 
parietal cells 
Peti-Peterdi et al., 2000 
NHE5 Neuronal tissues 
Endosomal pools  
Bobulescu et al., 2005 




NHE6 Trans-Golgi network 
Recycling endosomes 
Numata et al., 2006 
Nakamura et al., 2005 
Brett et al., 2002 
NHE7 Trans-Golgi network 
 
Nakamura et al., 2005 
Numata et al., 2006 
 
NHE8 Trans-Golgi network 
Kidney proximal tubules 
Mitochondria 
Goya et al., 2005 
Nakamura et al., 2005 
Numata et al., 2006 
 




to elicit various functions within the cell18. Figure A represents the topological 




Figure A: Topological model of the Na+/H+ exchanger 1(NHE1). 
  
The diagram depicts the orientation of transmembrane segments I–XII and the 
N-terminal (N) and C-terminal cytosolic tail (C) of NHE1. Adapted from 
Slepkov et al. 200519. 
 
 
1.1.2 Regulation of NHE1   
 
1.1.2.A Transcriptional regulation of NHE1 
 
To date, a number of transcription factors have been proposed to be involved 
in the regulation of the NHE1 gene which is located on chromosome 1 p35-
p36.120. Authors have determined an Activator protein-2 (AP-2) binding site 
within the NHE1 promoter region that drives NHE1 gene expression21. 
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Additionally, in renal tubular epithelial cells, acid influx mediated increase in 
NHE1 activity was postulated to be due to the increase in transcription factor 
Activator protein-1 (AP-1) activity22. 
 
More recently, the Hypoxia-inducible factor-1 (HIF-1) has been implicated in 
the regulation of NHE1 gene expression23,24. During hypoxia, the Hypoxia-
inducible factor-1 (HIF-1) is known to drive the expression of target genes that 
mediate angiogenesis. Interestingly, Mo and colleagues have demonstrated 
that human umbilical vein endothelial cells (HUVECs) that have been 
transfected with adenovirus encoding HIF-1α, induce NHE1 gene expression 
levels20,25.  
 
Apart from transcription factors, Besson et al.26 have shown that mitogenic 
stimulation induces NHE1 promoter activity during cell growth and 
proliferation. In particular, through genetic deletion and gel mobility shift 
assays, their work pinpointed towards the 0.9 and 1.1 kb region from the start 
site to be involved in directing the effects of mitogenic stimulants such as 
insulin, thrombin and growth factors26. 
 
In recent years, a strong association between intracellular reactive oxygen 
species (ROS) and cell survival or proliferation has become more evident. For 
instance, in Ras-transformed fibroblasts, an elevation in Superoxide (O2
•-) has 
been shown to increase proliferative capacity of the cells27-29. Moreover, a 
number of studies have shown the effect of O2
•- -induced inhibition of tumour 
cells’ sensitivity to apoptotic triggers30-33. Interestingly, NHE1 has been termed 
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as a redox regulated gene. By manipulating intracellular O2
•- levels, Akram et 
al34., demonstrated that an increase in O2
•- induces an increase in NHE1 gene 
promoter activity leading to enhanced NHE1 protein expression, which 
conferred survival advantage to the cell even in the presence of apoptotic 
triggers. This was reversed upon cells’ exposure to exogenous hydrogen 
peroxide which abrogated NHE1 promoter activity and gene expression, and 
enhanced cell sensitivity to death stimulus.  
 
1.1.2.B Regulation of NHE1 protein expression 
 
In general, the half-life of plasmalemmal NHE1 (24h) in both fibroblasts and 
PS120 cells has been described to prolonged as compared to other isoforms 
such as NHE2 (3h) and NHE3 (14h)35. Thus, the different half-lives of NHE 
isoforms suggests that the rates of protein synthesis and degradation may 
play a part on the turnover of a protein. Also, the specialized functions due to 
their tissue specificity, may account for the variation in the half-life of NHE 
isoforms. However, it is noteworthy to mention that regulation by other 
proteins or co-factors may be an important factor in extending its half-life of 
NHE1.  
 
The cytoplasmic C-terminus of NHE1 acts as an anchor for a class of 
interacting proteins known as the Calcineurin B homologous proteins 
(CHPs)36. CHP family of Ca2+-binding proteins are identified by their calcium-
binding regions that contain a characteristic EF-hand structural motif37,38. This 
family of proteins comprises of three isoforms (CHP1–CHP3) that share 
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homology with the calcineurin B subunit of the phosphatase39. Some of the 
functions of CHPs include constitutive vesicular trafficking40 and antagonizing 
calcineurin phosphatase activity41.  
 
CHPs are of particular interest as they have been implicated in the regulation 
of NHE1. Initial studies revealed that CHP1 is an essential cofactor that 
interacts closely with Na+/H+ exchangers (NHEs)42. Interestingly, recent work 
suggests that the interaction of NHE1 and CHP1 masks a disposal signal and 
therefore increases its plasma membrane localization and also regulates its 
antiporter activity43. Conversely, bound NHE1-CHP3 complex has been shown 
to enhance the stability of NHE1 at the cell surface. Intriguingly, CHP2 
expression appeared to be more tumour specific as its binding to NHE1 was 
postulated to be required for maintaining high pHi and the resistance to serum 
deprivation-mediated cell death in tumour cells44. Thus, based on the current 
evidence, it is likely the role of CHPs in the regulation of stability of NHE1 may 
vary depending on the cell or tissue type. 
 
The rate of synthesis and degradation dictates the intracellular level of a 
protein. Likewise, the type of regulatory mechanism that mediates the 
degradation of a protein may differ across cell lines. Increasing number of 
studies surrounds the role of the ubiquitin (Ub)–proteasome pathway (UPP) in 
the degradation of proteins (reviewed in 45). Moreover, studies have shown 
that most intracellular proteins residing in all tissue types are subjected to 
degradation via the ubiquitin (Ub)–proteasome pathway46. In a similar vein, 
Simonin and colleagues47 showed that the turnover of plasmalemmal NHE1 is 
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mediated by the NEDD4-1, an E3 ubiquitin ligase. Moreover, they proposed 
that NEDD4-1-mediated degradation of NHE1 protein occurs through the 
adaptor protein β-arrestin-1 which promotes ubiquitylation, endocytosis, and 
function.  
 
1.1.3. Physiological function of NHE1 
 
1.1.3.A pH and Cell Volume Regulation 
 
One of the most well-known functions of NHE1 is the regulation of intracellular 
pH (pHi) and cell volume. The transmembrane domain of NHE1 drives the Na+ 
for H+   exchange in a 1:1 ratio, conferring protection by avoiding acidification 
within the cell48. This mechanism occurs when the pHi within the cell declines 
and this eventuates in the rapid increase of exchanger activity to extrude the 
H+ ions and increase the pHi49. Apart from intracellular acidification, osmotic 
cell shrinkage also upregulates NHE1 activation. However, the mechanisms of 
NHE1 activation triggered by osmotic shrinkage are not completely 
understood. Recent evidence suggests that NHE1 interacts with several 
binding partners such as PIP2, ERM, and Calmodulin which in turn results in 
phosphorylation dependent changes that is able to restore the cell volume 






1.1.3.B Scaffolding function of NHE1 
 
Although NHE1 plays a key role in the regulation of pHi and cell volume50, it is 
also a significant membrane bound integrator of many signalling pathways 
and biological processes. Several line of evidence suggest its role in cellular 
functions that include, regulating cell shape, proliferation , migration and cell 
adhesion (reviewed in 51). Intriguingly, the cytoplasmic tail of NHE1 has been 
shown to act as a scaffold as it contains a vast number of binding sites for 
interacting partners to bind and elicit many of its functions52. Table 1 entails 
the list of binding partners of NHE1 and their corresponding binding and 



















Interacting Protein Amino acid binding 
regions or 
phosphorylation sites 
ERM ERM family proteins 508-512 and 552-560 
AKT Protein kinase B Ser 648 
ROCK RhoA kinase 638-815 
PIP2 Phosphatidylinositol 4,5-
bisphosphate 
513-520 and 556-564 
RSK Ribosomal S6 kinase Ser 703 
ERK 1/2 Extracellular signal-
regulated kinase 
Ser 770 and Ser 771 
NIK Nck-interacting kinase 538-638 
p38 p38 mitogen-activated 
protein kinase 
Ser 726 and Ser 729 
Cam (high affinity) Calmodulin  636-656 
Cam (low affinity) Calmodulin  664-684 
CamKII Ca2+  calmodulin-
dependent kinase II 
ND  
CHP1 Calcineurin B 
homologous protein 1 
515-530 
CHP2 Calcineurin B 
homologous protein 2 
515-530 
CHP3 (Tescalcin) Calcineurin B 
homologous protein 3 
509-571 and 633-815 
CA II Carbonic anhydrase II 790-802 




SHP-2 Protein tyrosine 
phosphatase 
ND  
Raf Raf kinase ND  
ARRB1 β- Arrestin-1 ND  
PFK-1 Phosphofructokinase 1 ND 
PPI Protein phosphatase 1 ND 
 
Table 2. Human NHE1 binding partners and phosphorylation sites 
List of NHE1 interacting proteins and their corresponding amino acid binding 
regions or phosphorylation sites. ND refers to the site of interaction not 






1.1.3.C Na+/H+ exchanger activity dependent / independent cell signalling  
 
NHE1 activity is significant in the regulation of various cellular functions. 
Several lines of evidence show that activation of NHE1 are able to defend 
against apoptosis through the inhibition of endonuclease53, caspase54 or the 
pro-apototic protein, Bax55. Additionally, the NHE1-mediated increase in pHi 
provides a permissive signal for cell-cycle progression and promoting cell 
proliferation by stimulating the synthesis of protein, RNA, and DNA18,56,57. 
Additionally, in the presence of apoptotic stress, NHE1 activation is crucial in 
the prevention of cell death through binding with ERM and activating PI3K/Akt 
pathway for cell survival.  
 
On the other hand, Denker and colleagues58 first demonstrated that NHE1 is 
involved in regulating cytoskeletal organization and cell shape through 
interaction with ERM proteins. In addition, they showed that NHE1–ERM 
association is not dependent on ion exchange, even in unstimulated cells58. 
Furthermore, our group has previously reported that O2
•--mediated cell 
survival involves an increase in the expression NHE1 despite exposure of the 
cells to apoptotic triggers34. Conversely, exogenous H2O2 exposure abrogated 
NHE1 gene expression, and enhanced cell sensitivity to apoptotic triggers. 
Moreover, over-expression of NHE1 may induce survival that may be 
independent of its activity as a pH regulator34. Hence, these findings suggest 
the possibility that NHE1 activity may not be an obligate requirement and 
correlate with its scaffolding function. However, the exact circumstances by 
which NHE1 activity is required still remains elusive. 
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1.1.4 Role of NHE1 in cancer progression 
 
It is well established that tumourigenesis is a complex process that is 
accompanied by an accumulation of  genetic alterations occurring in cells59. 
Therefore, understanding the molecular mechanisms that promote the 
stepwise progression of cancer from normal to malignant disease is of 
therapeutic relevance since cancer related deaths are mainly due to 
metastatic spread of tumorigenic cells.  
 
The three key in vivo tumor hallmarks comprises of low pHe, low serum 
content, and hypoxia that has been shown to be profound in  early  stages of 
tumor development60. Moreover, the close association of these three 
characteristics have been shown to involve NHE1 and define the tumor 
metabolic microenvironment61. 
 
To date, out of the nine mammalian isoforms of the Na+/H+ exchanger family, 
NHE1 was reported to play a critical role in the malignant progression of 
cancer51,62. For instance, in the presence of disturbed pH homeostasis, normal 
cells may encounter cell death or apoptosis, however, tumour cells are still 
able to survive the harsh extracellular acidification by exploiting a variety of 
membrane transporters and enzymes to regulate the pHi. Additionally, the 
acid base homeostasis differs between normal tissues and cancer cells.  
 
In a normal cell, the extracellular acid microenvironment (pHe) value ranges 
between 7.3-7.4 versus the intracellular pH (pHi) value 6.99-7.05. On the 
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contrary, in tumour cells, the pHe value tends to be more acidic 6.2-6.9 as 
compared to pHi values leaning towards an alkaline pH 7.12-7.763. Thus, the 
presence and sustenance of intracellular alkalinization and extracellular 
acidosis has been described as one of the hallmarks of tumourigenic cells62,64.  
 
Apart from a low pHe, the low serum content has been described as another 
hallmark of tumour microenvironment. Early studies first showed that serum 
deprivation upregulated NHE1 activity through a PI3K-dependent mechanism 
in invasive breast cancer cells. Paradiso et al.65, have demonstrated that the 
decrease in serum content promotes NHE1 dependent morphological and 
cytoskeletal changes in MDA-MB-435 breast cancer cells, followed by 
increased chemotaxis and invasion65. Furthermore, Pang and colleagues44  
have proposed that CHP isoform 2 (CHP2), which is abundant in tumour 
tissue types, has been shown to be complexed with NHE. They further 
demonstrated that cells are protected from death mediated by serum 
deprivation through maintaining an elevated pHi in malignant tumour cells44. 
Indeed, a recent study showed that the serum deprivation induces 
overexpression of Na+/H+ exchanger regulatory factor (NHERF1), which 
promotes Na+/H+ exchanger (NHE1)-dependent invasion in breast cancer 
cells through protein kinase A (PKA)-gated RhoA/p38 mediated signaling66. 
 
Hypoxia has been also been described as another primary hallmark of tumour 
microenvironment. Recent studies have demonstrated that in HT-1080 
fibrosarcoma cells, hypoxia stimulates p90 ribosomal S6 kinase (p90rsk) 
which triggers site-specific phosphorylation of the cytosolic tail of NHE1 and 
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concurrently result in the activation of NHE1. This action subsequently leads 
to enhanced invasive capability67. In addition, the capacity of NHE1 to mediate 
invasion in hypoxia induced human tongue squamous cell carcinoma68 or 
hepatocellular carcinoma69 has also been previously described. Altogether, 
these findings purport the fact that NHE1 is involved in enhancing the tumour 
metabolic environment for cancer progression. A summary of the different 
factors that regulate NHE1 and its impact on tumor hallmarks is summarized 




Figure B. The regulation of NHE1 and its roles in driving tumor hallmark 
behaviors.  
 
A schematic diagram depicting the major systems involved in the regulation of 
NHE1 activity leading to alkalinization of intracellular pH (pHi) and acidification 
of extracellular pH (pHe). Pertubance of intra-and extra-cellular environments 
trigger a series of events that promote tumor cell behaviors. (Adapted from 






1.1.5 Link between NHE1 and PI3K/Akt pathway in cell survival  
 
The regulation of NHE1 is complex due to its interaction with a variety of 
signalling molecules involved in different functions. Studies have highlighted 
the impact of NHE1 in modulating the activity of kinases such as mitogen-
activated protein kinases (MAPKs)70, p90 ribosomal S6 kinase (p90Rsk)71, 
Rho-activated kinase ROCK72,73, that have different roles in cell proliferation 
and death18. In a similar context, studies conducted by Wu and colleagues74, 
have demonstrated that NHE1 promotes cell survival via a dual mechanism – 
regulating cell volume and pHi through Na+/H+ exchange and by functioning 
as an anchor for the recruitment of a signalplex involving, ERM, PI3-Kinase, 
and Akt. Additionally, recent reports have shown that in the presence of 
apoptotic stress, NHE1-PIP2 binding is initiated, which then eventuates in 
PI3K activation and downstream activation of the Akt survival pathway75. 
Thus, this suggests a strong association between NHE1 and PI3K/Akt 
pathway in promoting cell survival.  
 
Additionally, using in vitro studies, authors have demonstrated that NHE1 
serves as a potential Akt substrate, through a Ser648 phosphorylation, which 
consequently increased its exchanger activity76. This was further supported by 
the fact that fibroblasts expressing NHE1-S648A mutants abrogated 
disassembly of actin stress fibers by platelet-derived growth factor and insulin 
and thus inhibited cell proliferation. Conversely, a similar finding involving 
cardiac myocytes showed that Akt-mediated Ser648 phosphorylation results in 
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dampens NHE1 activity. These conflicting studies purports the differential 
regulation of Akt induced NHE1 regulation in different cell or tissue types.  
 
Taken together, the above studies suggest that NHE1 acts as a scaffold for 
many of the proteins involved in the PI3K/Akt pathway and work together in 
conjunction to regulate survival. However, a key question that remains 




















1.2 PI3-Kinase (PI3K)/Akt Pathway 
 
1.2.1 Structure of Akt and its isoforms 
 
The ubiquitiously expressed Phosphoinositide 3-kinases (PI3Ks) have been 
reported to be involved in numerous cellular processes that include cell 
growth, proliferation, differentiation, metabolism and mobility77,78. In general, 
there are four classes within the PI3K family depending on the sequence 
homology, choice of substrate and tissue distribution79. Though three of the 
classes phosphorylate lipids, the class IV kinases (mTOR, ATM, ATR, DNA-
PK) are known to phosphorylate proteins80. Additionally, Class I which is more 
commonly studied, is sub-divided into 2 classes: Class IA, which comprises of 
a heterodimer consisting of one regulatory subunit (p85α, p85β, p55α, p50α, 
or p55γ) and one catalytic subunit (p110α, β or δ)81. Conversely, The Class IB 
heterodimer, composed of one regulatory subunit (p101 or p87) and one 
catalytic subunit (p110γ)81,82. Of the members of the Class 1A P13K, p110α 
and its regulatory subunit, p85, holds the most significance as it is commonly 
implicated in tumorigenesis 83. 
 
A key downstream substrate of PI3K is the pro-survival kinase PKB/Akt which 
has been shown to activate target proteins that have roles in various cellular 
functions. The family of serine/threonine kinases B/Akt represents one of the 
principal downstream mediator of the effects of the PI3K pathway. The Akt 
kinase belongs to the family of AGC kinases similar to that of protein kinase A 
(PKA) and Protein Kinase C (PKC)84. In mammalian cells, Akt, comprises of 
 17 
 
three highly homologous  family members, Akt 1, 2, and 3 that are encoded  
by three different  genes located on chromosome  14q32, 19q13 and 1q43 
respectively.  Studies have shown that these Akt isoforms share highly similar 
structures (Figure C), that include an N-terminal regulatory pleckstrin 
homology (PH) domain which binds phospholipids, a catalytic (CAT) domain 
for its kinase activity and a C-terminal extension (EXT) containing a regulatory 
hydrophobic motif (HM)85,86. Conversely, these isoforms possess distinct roles 
in the regulation of biological activities and are also expressed in different 
tissues87. For example, Akt 1 is a ubiquitously expressed protein as compared 
to Akt 2 that is expressed in the liver, skeletal muscle and adipose tissue or 




Figure C. Schematic diagram of Akt structure.  
 
The Akt structure comprises of three main domains, the N-terminal regulatory 
pleckstrin homology (PH) domain, a central catalytic (CAT) domain and a C-
terminal extension (EXT) containing a regulatory hydrophobic motif (HM). Akt 
phosphorylation occurs at Threonine 308(T308) and Serine 473 (S473) sites 






1.2.2 Activation of Akt  
 
In general, the signaling cascade is initiated upon stimulation by cognate 
growth factors leading to the recruitment of PI3K to the receptor tyrosine 
kinase. The activated p110α subunit of PI3K phosphorylates 
phosphatidylinositol—4, 5-biphosphate (PIP2) generating transient increase in 
the levels of phosphatidylinositol 3,4,5-triphosphate (PIP3)
89. The interaction 
between PIP3 and the PH domain of Akt results from the translocation of Akt 
from the cytosol to the plasma membrane, where it is phosphorylated at two 
principal regulatory sites, Serine 473 (Ser 473) and Threonine 308 (Thr 308), 
yielding an active kinase.  However, studies have revealed that TRAF6 
mediated ubiquitination at the PH domain acts as a recognition signal that 
promotes the translocation of Akt to be phosphorylated at both Thr308 and 
Ser473 sites90. 
 
Studies by Sarbassov and colleagues91 have shown that the phosphorylation 
at the Ser 473 site present at the carboxy-terminal (C-terminal) tail also known 
as hydrophobic motif (HM), by the mTORC2 complex comprising of  
mammalian target of rapamycin (mTOR), G L, and rictor , precedes the 
phosphorylation at the threonine 308 site located  in the activation loop by 
PI3K-dependent kinase 1 (PDK1). This was further supported as genetic 
deletion of both phosphorylation sites, suggests that phosphorylation on these 
two sites is a critical step for a full Akt kinase activation92. Although Akt activity 
is enhanced by approximately 100-fold through the Thr308 phosphorylation, 
the full activity of the Akt kinase requires the phosphorylation of Ser473 in the 
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hydrophobic motif93. Moreover, authors have demonstrated using mutant 
studies that both Thr308 and Ser473 phosphorylation of Akt appear to be 
phosphorylated independently of each other93. Contrastingly, recent studies 
illustrated that knockdown of Rictor within the mTORC2 complex or inhibitors 
of mTOR downregulated both Serine 473 and Threonine 308 phosphorylation. 
This supports the fact that the Serine 473 phosphorylation can facilitate 
Thr308 phosphorylation91,94,95. 
 
Following activation, the fully active Akt kinase then translocates to the 
cytoplasm and nucleus, to phosphorylate or interact with a multitude of 
molecular targets. Consequently, the effect of phosphorylating the 
downstream mediators in turn mediates the effect of Akt in regulating 
numerous cellular processes that includes cell growth and survival, migration 







Figure D: Activation and regulation of Akt.  
 
Growth factor (GF) induced activation of Receptor tyrosine kinases (RTKs) 
promotes the autophosphorylation and activates PI3K. PI3K drives the 
conversion of phosphatidylinositol-4,5-bisphosphate (PIP2) to generate 
phosphatidylinositol-3,4,5-bisphosphate (PIP3). PI3K activates Akt resulting in 
the recruitment of Akt to the membrane. This occurs through interaction 
between PH domain of Akt and PIP3 which induces a conformational change 
in Akt which recruits PDK1 to phosphorylate Thr308 and mTOR complex 2 
(mTORC2) phosphorylates Akt at the Ser473 site. Activated Akt dissociates 
from the membrane and mediates the phosphorylation a wide range of 
downstream targets involved in various cellular processes. PTEN 
(phosphatase and tensin homology) negatively regulates PI3K pathway. 
Dephosphorylation of Thr308 and Ser473 is mediated by protein phosphatase 










Phosphatases play pivotal roles in a cell as significant checkpoint regulators 
and switches through the dephosphorylation of many key signalling proteins. 
Some of the cellular functions regulated by phosphatases include cell cycle, 
differentiation and apoptosis98.  
 
The two main phosphatases involved in the negative regulation of Akt are PH-
domain phosphatases (PHLPPs) for the Ser 473 site99 and PP2A for the Thr-
308100,101. Thus dephosphorylation of Akt leads to the termination of its 
activity. Interestingly, studies indicate that FKBP51 (FK506 binding protein 
51), acts as a scaffold to promote the interaction between PHLPP and Akt 
thereby suppress the Akt phosphorylaiton at Ser 473 site102. On the other 
hand, the PML (promyelocytic leukemia protein) tumor suppressor has been 
shown to bind to both Akt and PP2A and promotes PP2A-induced Akt 
dephosphorylation at the Thr 308 site103. Interestingly, studies performed by 
Su and colleagues shows that phosphorylation at Thr 308 and Ser 473 sites 
act as recognition signals for Akt to be degraded via ubiquitin-proteasome 





1.2.3.B The Phosphatase and Tensin homolog deleted of chromosome 10 
tumour suppressor (PTEN) 
 
A widely known negative regulator of the PI3K/Akt pathway is the 
Phosphatase and Tensin homolog deleted on chromosome 10 (PTEN), which 
is a well characterized lipid and protein phosphatase that was initially 
discovered by two groups independently105,106. PTEN mediates its function by 
hydrolyzing the 3’ phosphate group on its substrate, PIP3 to generate PIP2, 
hence antagonizing the PI3K mediated downstream signalling events. In other 
words, it is through its lipid phosphatase activity, PIP3 levels are kept in check 
and Akt activation is suppressed. Thus, PTEN assists in regulating  the 
balance between cell proliferation and apoptosis within  a cell107. 
 
Apart from its role as a lipid phosphatase, PTEN can function in other 
biological processes. Song and colleagues108 have shown that the ability of 
PTEN to block cell cycle progression in the nucleus through the regulation of 
anaphase-promoting complex/cyclosome (APC/C) activity in the nucleus, 
occurs independent of its phosphatase activity. Furthermore, a recent study 
demonstrated that PTEN’s ability to regulate the size of DNA-damaged cells 
appears to be independent of its enzymatic activity, but through its interaction 
with an actin-remodeling complex that comprises of actin, gelsolin, and Eplin 
at the membrane109. 
 
On the other hand, since its discovery, a large body of literature has identified 
PTEN as commonly mutated tumor suppressor genes in various types of 
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human cancer which includes endometrial, skin and prostate cancers89,110. 
This was validated in vivo as PTEN-knockout mice led to the formation of 
tumors in various organs111,112. Moreover, studies have shown that germline 
mutations within the tumour suppressor, PTEN leads to two phenotypically 
different inherited diseases, namely, Cowden disease and Bannayan Zonana 
syndrome that are prone to cancer development113. 
 
A wide range of stimuli which includes growth factors can influence PIP3 
mediated signalling within a cell as it holds strong involvement in regulation of 
various physiological processes, such as cellular proliferation, survival, growth 
and motility. However, defects in the PIP3-dependent signalling seem to 
support tumourigenesis in cells114-116. The abrogation of negative feedback 
mechanisms may result in the amplification of PI3K/Akt signalling. 
Consequently, this leads to the accumulation of PIP3 in cells supporting the  
oncogenic transformation of cells mediated by hyperactivation of Akt117.  
 
1.2.4 Physiological role of Akt pathway 
 
Akt has been described to have an impact on the functional roles of many of 
its downstream targets. For instance, Akt mediated phosphorylation 
inactivates the function or expression of various pro-apoptotic proteins, 
inducing cell survival. This includes Akt phosphorylation of Bad on Ser136 site 
which leads to its sequestration by 14-3-3 proteins in the cytosol, promoting 
cell survival118. Similarly, Akt induces the phosphorylation of procaspase-9 at 
the Ser 196 site, which is accompanied by a decrease in caspase-9 activity in 
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vitro, preventing apoptosis119. The FOX transcription factors that belong to the 
other (O) subfamily (FoxO) proteins, are well-known downstream target of Akt 
that promote cell cycle arrest, DNA repair and apoptosis120.  Previous studies 
indicate that phosphorylation by AKT leads to inactivation of FoxOs through 
binding to 14-3-3 proteins that subsequently induces its export from the 
nucleus. This results in repression of transcription of target genes involved in 
apoptosis and cell-cycle arrest121. Further, Akt also induces the 
phosphorylation and translocation of the E3 ligase MDM2 to the nucleus 
where it antagonizes the function of the tumour suppressor p53, promoting 
cell survival122,123. 
 
Other functions carried out by Akt, includes cell growth, through its 
downstream target, mechanistic target of rapamycin (mTOR). A large number 
of studies have shed light on the role of Akt involving mTOR complex 1 
(mTORC1), that has been reported to promote cell growth through the 
regulation of translation initiation and ribosome biogenesis. (reviewed in 124). It 
has been shown that Akt mediated inhibitory phosphorylation of its 
downstream substrates such as, tuberous sclerosis complex 2 (TSC2) and 
proline-rich Akt substrate of 40 kDa (PRAS40), lead to the induction of 
mTORC1 signalling. This is followed by the activation of mTORC1 substrates 
such as translation initiation factor 4E binding protein 1 (4EBP1) and 
ribosomal protein S6 kinase, 70 kDa, polypeptide 1 (S6K1) that promotes 
protein synthesis and cellular proliferation125-129. Alternatively, recent evidence 
suggest mTORC2 may have implications in promoting protein synthesis 
through its interaction with ribosomal proteins130. Figure E depicts a model of 
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the Akt pathway and displays the downstream targets of Akt and its roles in 




Figure E: Akt signalling pathway and its role in various biological 
processes.  
 
Growth factor-induced Akt pathway mediates phosphorylation of its 
downstream substrates, including endothelial nitric oxide synthase (eNOS), 
p21, p27, glycogen synthase kinase 3 alpha (GSK3α)/(GSK3β), forkhead box 
O (FoxO) transcription factors, Bcl-2–associated death promoter (BAD), 
caspase 9, inhibitor of nuclear factor kappa-B kinase alpha (IKKα), proline-rich 
Akt substrate 40 (PRAS40), and tuberous sclerosis protein 2 (TSC2). The 
resulting cellular processes that are regulated through Akt mediated 
phosphorylation are indicated. Akt pathway is negatively regulated by PTEN, 






1.2.5 Akt in tumourigenesis 
 
1.2.5.A Role of Akt isoforms in cancer 
 
The current literature supports the role of the three isoforms of Akt 1, 2 and 3 
as downstream targets of PI3-Kinase that are involved in tumourigenesis by 
promoting cancer cell survival and growth131,132. Despite the structural 
similarities across the three Akt isoforms and mechanisms of activation, these 
isoforms have been reported to have distinct roles in tumourigenesis132.  
 
Numerous studies have highlighted the specific roles of Akt isoforms in 
tumourigenesis. For instance, using mouse models, Chen and colleagues133  
have demonstrated that Akt1 deficiency was able to dramatically reduce 
tumors in the prostate, endometrium, and small intestine tissues that were 
formed due to PTEN inactivation. Moreover, they also established that the 
haplodeficiency of Akt1 was enough to drastically abrogate the formation of 
high-grade prostate intraepithelial neoplasia (PIN) and endometrial 
carcinoma133. 
 
On the other hand, inhibition of Akt1 through specific siRNA, was shown to 
drastically enhance growth factor–induced cell migration in MCF10A breast 
epithelial cells, whereas no effect was observed through Akt2 inhibition134. 
Moreover, Yoeli-Lerner and colleagues135 had demonstrated that the 
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overexpression of Akt1 inhibited cell motility and invasion in tumorigenic 
breast cells. Thus Akt1 was thought to play a role as an inhibitor of migration 
and invasion in breast134,135 and ovarian cancer136. Furthermore, two different 
groups have demonstrated that different roles Akt isoforms involved in the 
initiation and invasive aspects of tumourigenesis137,138. 
 
In fact, emerging evidence supports the fact that Akt1 may be crucial in cell 
proliferation and primary tumor initiation and maintenance whereas Akt2 is 
thought to function mainly in metastatic dissemination cancer. For instance, 
abrogation of Akt1 function in mice displayed a delay in tumour progression 
and metastasis in ErbB2-induced mammary tumorigenesis139. Moreover, 
dissimilar to the role of Akt1, Akt2 has been implicated in promoting cell 
migration and invasion. In ErbB2-overexpressing breast cancer cell line, the 
overexpression of Akt2, but not Akt1, led to increased invasiveness in vitro 
and metastases in animal models140. Also, siRNA mediated knockdown of Akt 
2 in mammary epithelial cell lines have been shown to suppress the EMT-like 
morphological conversion134. Further, by inactivating Akt2, the invasive 
potential in glioma cells141 and lung adenocarcinoma cell line A549142 had 
been abolished. Conversely, downregulation of Akt1 and Akt2 has been 
shown to promote migration and invasion in PC3 prostate cancer, suggestive 
of the role of isoform-specific Akt in the regulation of cell motility in different 
types of cancer143.  
 
Though most studies have focused mainly towards Akt isoform 1 and 2, the 
role of Akt isoform 3 in tumourigenesis has been recently implicated in 
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melanoma. However, due to its tightly regulated tissue specific distribution in 
comparison to other isoforms144,145. Taken together, it is likely that Akt 
isoforms may switch to influence the invasive or metastatic potential of 
tumors. However, it is noteworthy to say the abundance or activation of Akt 
isoforms may also vary in different cellular contexts. 
 
1.2.5.B Hyperactivation of Akt 
 
In the complex cascade of signalling within in a cell, the presence of cross-talk 
and feedback loops often influences the regulation of Akt kinase. Conversely, 
genetic alterations such as mutations in the catalytic PI3K subunit, receptor 
tyrosine kinase or Ras activation can also lead to tumorigenesis resulting in 
aberrant Akt activation146. Various human cancers such as glioblastoma 
multiforme and hematological malignancies have shown to incur 
hyperactivation of Akt in which studies have also demonstrated high 
correlation between tumor Akt activation and advanced stage disease in 
selected tumor types147. For example, one particular study performed by Sun 
and colleagues148 estimated that 40% of breast and ovarian cancers and more 
than 50% of prostate carcinomas demonstrated increased Akt1 kinase 
activity149. Moreover, the increase in Akt1 kinase activity in approximately 80% 
of tumours was shown to have transitioned to high grade and stage III//IV 
carcinomas149. Interestingly, one of the most common genetic mutations 
linked with the aberrant activation of the PI3K/Akt pathway is the result of the 
loss of PTEN function115. Research has shown that impaired or deletion of the 
tumour suppressor gene, display oncogenic activation of Akt  in sporadic 
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tumours with approximately 60% in advanced prostate cancer and 70% in 
glioblastomas105. Additionally, some of the oncogenic processes that Akt is 
involved in includes, cell growth, epithelilal mesenchymal transition (EMT), 
angiogenesis and metastasis150-152. 
 
Also, recent studies by Carpten et al. suggest that a substitution of glutamic 
acid to lysine within the PH domain of Akt1 (E17K), drives the transform of 
ation Rat fibroblasts and induce leukaemia in mice. Moreover, this mutation 
has been reported to give rise to constitutive membrane localization and 
detected in human breast, colorectal, and ovarian cancers153. Strikingly, upon 
screening 65 melanoma cell lines, the E17K mutation was also found to be 
present in the Akt3 isoform despite the absence of E17K mutations were 
identified in Akt1 or Akt2145.  
 
1.2.5.C Role of Hsp90 in the stability of Akt 
 
Hsp90 (Heat shock protein 90) molecular chaperone is a 90 kDa protein that 
is involved in maintaining stability, proper folding and the function of a 
multitude of signalling proteins involved in various cellular processes154. A 
wide range of signalling molecules such as protein kinases, transcription 
factors that are involved in the cell homeostasis, growth, differentiation, and 
apoptosis  have been identified for substrates as Hsp90155-158. 
 
The structure of Hsp90 represents a flexible homodimer, with each monomer  
divided into three domains, namely, the N terminal, the middle domain (client-
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binding site) and the C terminal (co-chaperones binding site)159,160. The 
chaperone cycling involves the binding of Hsp90 to its client protein and 
together with the aid of co-chaperones like the Hsp70/Hsp40, Cdc37, Hop, 
p23 and Aha1 to support the proper folding and prevents aggregation 
(reviewed in 161). Importantly, this process is driven by the mandatory 
involvement of hydrolysis of ATP to ADP160. It is through this process, that 
Hsp90 displays its dual function of ensuring the proper conformational 
development of newly synthesized proteins and promoting the degradation of 
unfolded proteins162,163. Hence, this mechanism enables the Hsp90 complex 
to preserve the function of client proteins even in the presence of cellular 
stressors164.   
 
Molecular chaperones play an important role in numerous signaling pathways 
which are strongly linked to cell survival and proliferation, however, an 
elevation in their activity often results in tumourigenesis. Hsp90 has been 
implicated in many cancers due to its contribution to tumour cell survival 
through the stabilization of aberrant signalling proteins and by interfering with 
apoptotic pathways164,165. One of its major client proteins includes the 
oncogenic kinase, Akt, which has been shown to be dependent on Hsp90 for 
its stability166. Using mutant studies, Sato and colleagues167 demonstrated that 
Hsp90 confers protection to Akt, through its interaction and subsequently 
prevents it from PPP2A- mediated dephosphorylation in vivo. Thus, this 
mechanism allows the chaperone, Hsp90 to protect the kinase activity of Akt. 
In line with this notion, it is likely that the oncogenic mutation of Akt, could 
possibly necessitate the increase in requirements for HSP90 function in these 
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cells due to its aberrant conformation of Akt. Accordingly, several lines of 
evidence have documented elevated levels of Hsp90 in a number of 
malignancies such as ovarian, breast and haematological malignancies168-170. 
This is further supported by the fact that the inhibition of Hsp90 promoted the 
proteasome mediated degradation of Akt in breast cancer cell lines166. Thus it 
is likely, that malignancies that inherit the hyperactivation of Akt, Hsp90 may 

























AIM OF STUDY 
 
Independent reports from our group suggest O2
•- mediated survival in tumour 
cells involves two targets, NHE1 and Akt34,171. Interestingly, preliminary data 
from our group demonstrated that in cells that lack the tumour suppressor 
PTEN, hyperphosphorylation of Akt and increased NHE1 expression were 
observed, as compared to its wildtype counterpart. In contrast, silencing NHE1 
led to the dephosphorylation of Akt in MEFPTEN-/- cells but not in MEFPTEN+/+ 
cells. Although the Na+/H+ Exchanger 1 (NHE1), a membrane antiporter, has 
been implicated in tumour cell survival, the regulation of its expression in 
tumour cells is not completely understood.  
 
In the current study, we aim to establish the mechanism by which NHE1 
expression is regulated in MEFPTEN-/- cells. In addition, we aim to investigate 
the mechanism by which NHE1 and Akt may be part of a feedback loop that 
might be crucial in tumour cell survival. Results from this study will also be 
tested in the MCF10AT1Kcl.2 breast cancer series for its physiological 
relevance findings. We propose that our findings might be critical for the 
development and maintenance of tumour cells and may help to establish a 








2.1.1 Chemicals and reagents 
Company Chemical Reagents 
Hyclone (UT, USA) Dulbecco’s modified Eagle’s medium 
(DMEM), Roswell Park Memorial 
Institute-1640 (RPMI-1640) Foetal 
bovine serum (FBS), Phosphate 
Buffered Saline (PBS), Trypsin,  
L-glutamine  
 




San Diego, CA) 
LY294002 
Lonza (Walkersville, MD, 
USA)  
 
Gentamicin Sulphate  
 
Invivogen (San Diego,USA) Geldanamycin 
Sigma-Aldrich, MO, USA  
 
Triton X-100, Aprotinin, Pepstatin A, 
Phenylmethanesulfonyl Fluoride 
(PMSF), Leupeptin, 
Sodium orthovanadate, RNAase A,  
Dithiothreitol (DTT), Bovine Serum 




Pierce (Thermo Fisher 
Scientific Inc, Rockford, IL, 
USA) 
Coomassie PlusTM Protein assay 
reagent, RestoreTM Western Blot 
stripping buffer, Supersignal west 
Pico chemiluminescent substrate 
BD Pharmingen, USA  
 
Cell lysis buffer (1X)  
 
Merck KGaA, Darmstadt, 
Germany  
 
Methanol, Hydrogen peroxide, 













Pierce (Pierce, Thermo 
Fisher Scientific Inc, 
Rockford, IL, USA 
Horseradish peroxidase (HRP)-conjugated 
goat Anti-mouse secondary antibody 
DakoCytomation (Glostrup, 
Denmark) 
Horseradish peroxidase (HRP)-conjugated 
goat Anti-mouse secondary antibody 
Chemicon (CA,USA) Mouse monoclonal Anti-NHE1 
Upstate biotechnology (Lake 
placid, NY,USA) 
Rabbit polyclonal Anti-Cu/ZnSOD 
 
 
Cell Signalling Technology 
Inc. (Beverly, MA, USA) 
 
Rabbit polyclonal Anti-PTEN 
Rabbit polyclonal Anti-P4D1 
Rabbit polyclonal Anti-Pan Akt 
Rabbit polyclonal Anti-Akt1 
Rabbit polyclonal Anti-Akt2 
Rabbit polyclonal Anti-Akt3 
Rabbit polyclonal Anti-phospho Akt Ser473 
Rabbit polyclonal Anti-phospho Akt Thr308 
Rabbit polyclonal Anti-mTOR 
Rabbit polyclonal Anti-Rictor 
Rabbit polyclonal Anti-phospho GSK3α/β 
Ser21/9 
Rabbit polyclonal Anti-VDAC 
 
Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) 
Mouse monoclonal anti-Hsp90 
Sigma-Aldrich (St. Louis, 
USA) 
Mouse monoclonal Anti-β-actin 
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2.1.3 Cell lines and cell culture 
 
PTEN wildtype (MEFPTEN+/+) and PTEN-null mouse embryonic fibroblasts 
(MEFPTEN-/-) were obtained from Dr Tak W. Mak (University Health 
network,Toronto, Ontario, Canada). Both cell lines were grown in 5% CO2-
humidified incubator at 37°C, in Dulbecco’s modified Eagle’s medium/high 
glucose (DMEM) supplemented with 10% fetal bovine serum (FBS), 2mM L-
Glutamine and 1mM Gentamicin.  
 
The MCF10AT1kcl.2 series of breast epithelial cells were purchased from  
Karmanos Cancer Institute, Detroit, MI. The MCF10AT1kcl.2 series of cell 
lines were grown in 5% CO2-humidified incubator at 37°C, in complete 
medium containing Dulbecco’s modified Eagle’s medium/Ham’s F-12 (Gibco), 
5% horse serum, L-Glutamine, 15 mmol/L (HEPES), Sodium pyruvate, 0.1 
μg/ml cholera toxin ,10 μg/ml insulin, 0.5 μg/ml hydrocortisone, 0.02 μg/ml 




2.2.1 RNA Interference (RNAi) Assay 
 
Cells were transfected at approximately 50% confluency. Prior to transfection, 
cells were replaced with fresh medium without antibiotics. Cells were 
transfected with small interfering RNA (siRNA) using Lipofectamine RNAiMAX 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. 
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Both control siRNA and siRNA of target gene was mixed with lipofectamine 
RNAiMAX (Invitrogen, Carlsbad, CA, USA) in the Opti-MEM®I reduced serum 
medium in 1:1 ratio. The mixture was mixed and incubated for 20 minutes and 
added drop-wise into each well. 15-16 hours post-transfection, cells were 
washed with 1xPBS and replaced with fresh medium. Cells were harvested for 
various assays either at 48 or 72 hours post transfection. 
 
Transfection was performed using the following siRNAs. 
 
siRNA for mouse Akt1 (ON-TARGETplus SMARTpool) and Human Akt1/2 
(ON-TARGETplus SMARTpool) was purchased from Dharmacon (Thermo 
Scientific, IL, USA). Concentration of mouse Akt1 or Human Akt1/2 siRNA 
used was 150nM. 
 
siRNA for mouse or Human Hsp90 was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Concentration of mouse or Human 
Hsp90 siRNA used was 150nM. 
 
Control siRNA which is non-homologous to any known gene sequence 
(QIAGEN, Valencia, CA, USA) was used as a negative control. 
  
2.2.2 RNA Extraction and Real-Time PCR 
 
Total RNA was isolated using the RNAeasy Mini kit (Qiagen) according to the 
manufcturer’s description. The concentration and quality of the RNA was 
 37 
 
determined with NanoDrop ND-1000 spectrophotometer (Thermo scientific, 
Thermo Fisher Scientific Inc, Rockford, IL,USA). 
 
Reverse-transcription PCR was performed using the TaqMan® Reverse 
Transcription Reagent (Applied biosystems) according to the manufacturer’s 
protocol. Briefly, total RNA was reverse transcribed 10 μl reactions consisting 
of 1.1U/ μl MultiScribe™ reverse transcriptase, 425 μM of each dNTPs, 1X 
Taqman RT buffer, 2 μM random hexamers, 5mM MgCl2, 0.35U/ μl RNase 
inhibitor and DEPC treated water. Reverse transcription reaction was carried 
out in Mastercycler gradient (Eppendoff, USA) at 25 °C for 10 min, 37°C for 60 
min and a final step of 95°C for 5 min. 
 
NHE1 gene expression levels were measured by performing Real-time PCR 
using TaqMan specific primers purchased from Applied Biosystems. Briefly, a 
50μl reaction comprising of 5 μl of RT product was mixed with 1X TaqMan® 
Universal PCR Mastermix, 2.5 μl of 20x specific TaqMan probe, 2.5 μl of 18S 
rRNA TaqMan probe, made up to 50 μl with DEPC water. A negative control 
consisting of sterile water only and another control with RT mix only was 
included to check for contamination. Ribosomal RNA (18S) was used as an 
internal control. All Real-Time PCR reactions were performed in StepOne 





2.2.3 Sodium Dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blot analysis 
 
Cells were harvested in PBS and subjected to centrifugation at 14,000rpm for 
10 minutes. The cell pellet was lysed in the lysis buffer (50mM Tris-HCl pH7.4, 
150mM NaCl, 1mM EGTA, 1mM EDTA, 0.5% (v/v) Triton X-100) 
supplemented with protease inhibitors (1mM PMSF, 5μg/ml leupeptin, 5μg/ml 
pepstatin A, 1μg/ml aprotinin and 1mM of sodium orthovanadate). The lysate 
was then centrifuged at 14,000rpm for 10 minutes. Protein concentration of 
cell lysate was determined  using Coomassie Plus™ Protein assay reagent 
(Pierce, Thermo Fisher Scientific Inc, Rockford, IL, USA),according to 
manufacturer’s instructions. 
 
Protein samples were diluted with the 5x loading dye (0.313M Tris HCl (pH 
6.8), 10% SDS (w/v), 0.05% bromophenol blue, 50% glycerol and 0.5M DTT) 
and warmed at 37°C for 5min prior to loading the gel. Between 50-70μg of 
protein (depending on protein of interest) was loaded per lane for SDS-PAGE 
analysis. Depending on the size of the protein of interest, 4% stacking gel and  
resolving gel (varying between 6.5%-15%) was prepared. Gels were run using 
the Bio-Rad Mini-PROTEAN 3 Cell (CA, USA). The pre-stained Kaleidoscope 
marker (Bio-Rad, CA, USA) was used to determine the approximate molecular 
sizes of the proteins bands obtained.  Resolved proteins were transferred onto 
a nitrocellulose membrane by the wet transfer method at 350mA for 1h using 
the Bio-Rad Mini Trans-Blot Electrophoretic Transfer Cell (CA, USA). The 
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membranes were then blocked in 5% fat-free milk in Tris-buffered saline 
/Tween 20 (TBST) (20 mM Tris-HCl, pH 7.6, 137mM NaCl, 0.1% Tween 20), 
on a shaker at room temperature for 1h. TBST was used to rinse the 
membrane and remove excess milk prior to incubation with primary antibodies 
(diluted in 5% (w/v) BSA) overnight at 4°C. Membranes were washed three 
times with TBST, at 5 minute intervals to remove the unbound primary 
antibody. The membrane was then incubated with horseradish peroxidase 
conjugated secondary antibodies (diluted in 5% (w/v) milk) for 1 hour at room 
temperature. Enhanced Chemiluminscence (ECL) Detection was performed 
using the Supersignal West Pico chemiluminescent substrate (Pierce, Thermo 
Fisher Scientific Inc, Rockford,IL, USA). For the detection of various proteins 
on the same blot, the Restore Western Blot Stripping Buffer was used to strip 
the membrane and reprobing for different proteins. Densitometric analysis of 
protein bands on film was assessed using FujiFilm Multigauge V3.0.  
 
2.2.4 Membrane/Cytosol fractionation 
 
Cells were harvested and washed once with ice-cold PBS. The cell pellet was 
resuspended in lysis buffer (20mM HEPES (pH 7.4), 5mM NaCl, 10mM 
MgCl2, 1mM EDTA) supplemented with protease inhibitors (1mM 
phenylmethylsulfonyl fluoride (PMSF), 1μg/ml leupeptin, 1μg/ml pepstatin A, 
1μg/ml aprotinin and 1mM sodium orthovanadate). Cell lysate was 
homogenized using a dounce homogenizer (20 times) in ice. The debris was 
removed by centrifugation at 500g for 5 minutes at 4°C. Homogenized 
fractions were subjected to high speed centrifugation at 100,000g for 50 
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minutes, at 4°C. The cytosolic fraction was removed and stored at -80°C. The 
resulting cell pellet was lysed in lysis buffer containing 50mM Tris-HCl pH7.4, 
150mM NaCl, 1mM EGTA, 1mM EDTA, 0.5% (v/v) Triton X-100, 
supplemented with protease inhibitors. After lysis, the fraction was subjected 
to centrifugation at 14,000rpm for 10 minutes. The supernatant (membrane 
fraction) was analyzed together with cytosolic fractions by Western blot. For 
membrane fractionation, VDAC and SOD1 were used as membrane and 
cytosolic markers respectively. 
 
2.2.5 Immunoprecipitation assay 
 
Immunoprecipitation with anti-NHE1 
 
Cells were harvested and washed once with ice-cold PBS. The cell pellet was 
resuspended in lysis buffer (20mM HEPES (pH 7.4), 5mM NaCl, 10mM 
MgCl2, 1mM EDTA) supplemented with protease inhibitors (1mM 
phenylmethylsulfonyl fluoride (PMSF), 1μg/ml leupeptin, 1μg/ml pepstatin A, 
1μg/ml aprotinin and 1mM sodium orthovanadate). Cell lysate was 
homogenized using a dounce homogenizer (20 times) in ice. The debris was 
removed by centrifugation at 500g for 5 minutes at 4°C. The lysate was 
incubated with Protein A/G agarose beads, anti-NHE1 or control IgG with 
gentle rocking, overnight at 4°C. The immunoprecipitates were washed three 
times with 1X PBS (with inhibitors) prior to the addition of loading dye and 
heating at 37°C for 5 minutes. Immunoprecipitates and inputs were assessed 
by Western blot analysis to detect the NHE1 interacting proteins. 
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Immunoprecipitation with Anti-Akt 
 
Cells were harvested and washed once with ice-cold PBS. Cell pellet was 
lysed in the lysis buffer (50mM Tris-HCl pH7.4, 150mM NaCl, 1mM EDTA, 
0.5% (v/v) NP-40, 0.5% (v/v) Triton X-100) containing protease inhibitors. Cell 
lysate was collected by centrifugation at 5000rpm for 10 minutes. The lysate 
was incubated with Protein A/G agarose beads, anti-Akt or control IgG with 
gentle rocking, overnight at 4°C. The immunoprecipitates were washed three 
times with 1X PBS (with inhibitors) prior to the addition of loading dye and 
heating at 37°C for 5 minutes. Immunoprecipitates and inputs were assessed 
by Western blot analysis to detect the Akt interacting proteins. 
 
2.2.6 Statistical Analysis 
 
The data was statistically analysed using the Student’s t-test (Microsoft Excel 











CHAPTER 3: RESULTS 
 
3.1 NHE1 is a Hsp90 client protein  
 
3.1.1 Increase in NHE1 protein expression in MEFPTEN-/- cells compared to 
MEFPTEN+/+ cells does not correlate with an increase in NHE1 mRNA 
production  
 
The Na+/H+ exchanger 1 (NHE1) protein is one of the many ion-exchangers 
that tightly control the pH gradients in normal cells. Apart from its role as a 
sodium-proton exchanger and pH regulator, NHE1 has been documented to 
be a regulator of physiological processes such as cell proliferation, cell 
differentiation and cell migration51,52,172. However, the perturbance of pH 
homeostasis often leads to the alteration of many processes which may result 
in tumour progression. In addition, the increased expression of NHE1 protein 
levels may contribute towards the malignant transformation of cells173,174. 
Thus, in the current study, we aim to establish the mechanism by which NHE1 
protein expression is upregulated in MEFPTEN-/- cells compared to MEFPTEN+/+ 
cells.  
 
To assess this, MEFPTEN+/+ and MEFPTEN-/- cells growing in 10% fetal bovine 
serum (FBS) were collected and whole cell lysates were examined by 
immunoblot to analyse the expression of NHE1 and PTEN (Figure 1). As a 
control for our analysis, PTEN was only detected in MEFPTEN+/+ and not in 
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MEFPTEN-/- cells. NHE1 is an ubiquitiously expressed protein that comprises of 
two forms. The glycosylated (mature) form which is expressed at the cell 
membrane with a molecular mass that ranges between 90∼110 kDa and the 
unglycosylated (immature) form with a molecular mass ∼85kDa175. We found 
that the mature NHE1 appeared to be significantly increased in MEFPTEN-/- 
cells as compared to MEFPTEN+/+ cells. Thus, we were keen to know whether 
the increase in NHE1 expression in MEFPTEN-/- cells was transcription 
dependent. 
 
    
Figure 1: Increased NHE1 protein expression in MEFPTEN-/- cells as 
compared to MEFPTEN+/+ cells.  
 
MEFPTEN+/+ and MEFPTEN-/- cells were grown in DMEM/10% FBS for 24 hours 
and assessed by western blot analysis NHE1 and PTEN expression levels.   
β-Actin was used as loading control. A representative blot from at least two 
independent experiments is shown. 
 
 
In most cases, the mRNA expression level is said to directly correlate to the 
protein expression level. Hence, to determine if the increase in NHE1 
expression observed in MEFPTEN-/- cells is transcriptionally mediated, NHE1 
mRNA levels were assessed in both MEFPTEN+/+ and MEFPTEN-/- cells lines by 










levels in MEFPTEN-/- cells were higher than control cells by approximately 0.1 
fold difference and statistically significant. However, this may not be sufficient 
to cause a drastic increase in protein levels. Hence, this data proposes the 
first line of evidence that the increase in NHE1 protein abundance observed in 
MEFPTEN-/- cells may not be due to the increase in gene transcription. Thus, 
this gives rise to the possibility that a decreased rate of protein turnover or 
degradation may be associated with the increased NHE1 expression in 




Figure 2: Increase in NHE1 protein expression in MEF PTEN-/- cells is not 
transcriptionally mediated 
 
MEFPTEN+/+ and MEFPTEN-/- cells were grown in DMEM/10% FBS for 24 hours 
and NHE1 mRNA levels were assessed by Real-Time PCR. The data 
represents the mean±S.E. from four independent experiments done in 










































3.1.2 NHE1 protein stability is prolonged in MEFPTEN-/- cells as compared 
to MEFPTEN+/+ cells   
 
Having ruled out the possibility that an increase in gene transcription as a 
cause for elevated NHE1 protein levels in MEFPTEN-/- cells compared to 
MEFPTEN+/+ cells, we next asked if it may be due to the increased half-life of 
the NHE1 protein. In general, the half-life of a protein refers to the rate of 
turnover that can occur in a cell or tissue type176. In addition, the half-life of a 
protein may be used to evaluate the protein stability for comparison between 
wildtype and mutant cells. To assess the stability of NHE1 protein in both cell 
lines, we utilized Cycloheximide (CHX) which works as a global inhibitor of de 
novo protein synthesis to study the half-life of the NHE1 protein. We studied 
the time-course of intracellular NHE1 degradation by administering 100 µg/ml 
of CHX, a protein synthesis inhibitor, to MEFPTEN+/+ and MEFPTEN-/- cells.  
 
Analysis by western blot showed that the administration of CHX (100μg/ml) 
was able to cause complete inhibition of c-Myc protein synthesis (positive 
control), which has a known half-life of less than 30 minutes177, in both cell 
lines. Results presented herein demonstrate that the NHE1 protein levels was 
significantly diminished by the 48 hour timepoint in MEFPTEN+/+ cells (Figure 
3A) as compared to MEFPTEN-/- cells (Figure 3B), which displayed a delay in 
the degradation of mature NHE1 levels. Interestingly, the immature NHE1 
protein expression is diminished in all CHX-treated lanes in both cell lines 




The data presented in Figure 3C represents the densitometric analysis of the 
percent of mature NHE1 levels remaining upon treatment with CHX in both 
cell lines. We show that the estimated half-life of mature NHE1 in MEFPTEN+/+ 
cells was estimated to be ~40 hours as compared to the prolonged 
degradation of mature NHE1 at ~68 hours in MEFPTEN-/- cells. Taken together, 
our data concludes that the mature NHE1 protein appears to have an 
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Figure 3: NHE-1 protein is more stable in MEFPTEN-/- cells as compared to 
MEFPTEN+/+ cells  
 
MEFPTEN+/+ and MEFPTEN-/- cells were grown in DMEM/10%FBS and treated 
with 100μg/ml cycloheximide (CHX) or DMSO as a control at 70% confluency. 
Cell lysates were harvested at various timepoints between 24-72hrs post-
treatment with or without CHX treatment. (A) MEFPTEN+/+ and (B) MEFPTEN-/- 
cells lysates were assessed by western blot to detect NHE1, c-Myc and β-
actin (loading control). (C) For densitometric analysis, the expression level of 
NHE1 in (A) and (B) was normalized to β-actin and normalized to its 
respective controls and are reported as percent remaining (horizontal dotted 
line represents 50% level of NHE1 protein remaining). t1/2 refers to the half-life 
of NHE1 at 50% level of NHE1 protein remaining. The data represents the 
mean±S.E. from three independent experiments, * p < 0.05, Student’s t-test, 








3.1.3 Proteasome inhibition increases NHE1 stability in MEFPTEN+/+ cells 
but have no effect in MEFPTEN-/- cells 
 
Having established that NHE1 displays prolonged stability in MEFPTEN-/- cells 
as compared to wildtype cells in Section 3.1.2, we next reasoned that this may 
be due to a decrease in protein turnover in MEFPTEN-/- cells. Studies have 
shown that the Ubiquitin Proteasome Pathway (UPP) is one of the 
mechanisms that the cell employs to regulate turnover of most short- and 
long-lived proteins45.  Thus, we incubated both cell lines for 3 h with MG132, a 
drug that inhibits the 26S proteasome function without disturbing normal 
cellular functions such as ATP metabolism and protein synthesis178.  
 
Western blotting analysis demonstrated the significant increase in levels of 
NHE1 in response to MG132 treatment in MEFPTEN+/+ cells (Figure 4A). This 
was not surprising as MG132 mediated inhibition of the proteasome 
machinery would result in the accumulation of non-degraded proteins. In 
contrast, in the presence of MG132, the cellular levels of NHE1 do not 
significantly change in MEFPTEN-/- cells (Figure 4B). The relative intensity of 
NHE1 levels in both cell lines were assessed by densitometry in MG132 
treated and untreated samples (Figure 4C). The data further confirmed that 
addition of MG132 caused upregulation in NHE1 expression in MEFPTEN+/+ 
cells by approximately 2.2 fold as compared no significant difference was 
observed in NHE1 levels in MEFPTEN-/- cells. Together, these experiments 
support that the normally shorter half-life of NHE1 protein in MEFPTEN+/+ cells 
may be due to its rapid turnover via the proteasome, raising a possibility that 
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Figure 4: MG132-mediated inhibition of proteasome degradation 
complex displays no effect on NHE1 protein expression in MEFPTEN-/- 
cells 
 
(A) MEFPTEN+/+ and (B) MEFPTEN-/- cells were grown in DMEM/10%FBS and 
treated with 10μM of MG132 (or DMSO as a control) for 3 hours. Cell lysates 
were harvested and assessed by western blot to detect NHE-1 and β-actin 
(loading control). (C) Densitometry analysis of NHE1 band intensity from (A) & 
(B). A representative blot is shown from at least five independent experiments 
The value represents the mean±S.E. of five independent experiments, *p-






















































3.1.4 Hsp90 may be involved in stabilizing NHE1 protein expression in 
MEFPTEN-/- cells  
 
Based on our results so far, we have shown that NHE1 protein in MEFPTEN-/- 
cells displays increased stability as compared to its wildtype counterpart and 
MG132 -mediated inhibition of proteasome activity appears to have no effect 
on increasing NHE1 protein abundance in MEFPTEN-/- cells. However, the 
factors attributing to the prolonged stability of NHE1 protein in MEFPTEN-/- cells 
still remain undetermined. Thus, we questioned if molecular chaperones could 
be accounted for the increased stability of NHE1.  
 
The Hsp90 is an abundant cytosolic protein that acts as a ‘molecular 
chaperone’ and play various roles including stabilizing proteins, refolding of 
denatured proteins, and promoting cell survival162. Furthermore, it has been 
shown to interact with other co-chaperones and cofactors to carry out its role 
in folding and conformational regulation of its client proteins that include 
signalling kinases such as Raf-1, p53 and Akt179. Apart from maintaining 
proper protein folding, increased expression of Hsp90 has been detected in 
tumor cells and has been shown to facilitate the survival of malignant cells180. 
Thus, we next examined if the chaperone molecule Hsp90 may be involved in 
regulating the stability of NHE1 expression in MEFPTEN-/- cells.  
 
We first assessed the localization of Hsp90 in MEFPTEN-/- cell lines through 
membrane-cytosol fractionation. The inputs were assessed on a separate gel 
to detect for the membrane fraction control, VDAC and cytosolic control, 
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Cu/ZnSOD (Figure 5A). Surprisingly, Hsp90 protein was not only detected in 
the cytosolic fraction but also the membrane fraction in both cell lines (Figure 
5B). However, the Hsp90 expression level appeared to be more abundant in 




























Figure 5: Hsp90 is present at the membrane in MEFPTEN-/- cells 
 
(A) MEFPTEN-/- cells were grown in DMEM/10% FBS for 24 hrs. Cell lysates 
were subjected to membrane-cytosol fractionation and analysed by western 
blot to detect VDAC (membrane fraction control) and Cu/ZnSOD (cytosolic 
control). (B) Detection of NHE1, Hsp90 by immunoblot analysis. β-actin was 
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3.1.5 Increased binding of Hsp90 and NHE1 protein in MEFPTEN-/- cells  
 
The detection of Hsp90 at the membrane in MEFPTEN-/- cells (Figure 5) led us 
to question whether Hsp90 interacts with NHE1 at the plasma membrane. 
Using a primary antibody against NHE1, we performed co-
immunoprecipitation to detect possible complex formation between NHE1 and 
Hsp90. Interestingly, our studies revealed a co-precipitated Hsp90 protein 
band which was enhanced in MEFPTEN-/-cells but almost undetectable in 
MEFPTEN+/+ cells (Figure 6). Moreover, our data showed no band was 
observable in the lane where IgG control antibody was used. Together, our 
data suggests NHE1-Hsp90 complex is enhanced in MEFPTEN-/- cells as 
compared to normal cells. This may be due to increased expression of Hsp90 















Figure 6: Enhanced binding of NHE1 to Hsp90 in MEFPTEN-/- cells as 
compared to MEFPTEN-/- cells 
 
MEFPTEN+/+ and MEFPTEN-/- cells grown in DMEM/10% FBS for 24 hours. Cell 
lysates were subjected to membrane-cytosol fractionation. The membrane 
fraction was then used and immunoprecipitated with anti-NHE1 or control IgG 
antibody. The precipitates and input were analysed by western blot using 
antibody against Hsp90 and NHE1. A representative blot is shown from at 




3.1.6 Effect of inhibition of Hsp90 activity on NHE1 expression in 
MEFPTEN-/- cells  
 
3.1.6.A Hsp90 prevents degradation of NHE1 in MEFPTEN-/- cells  
 
We next investigated whether Hsp90 may be the candidate chaperone that 
might be involved in protecting NHE1 from proteasome -mediated degradation 
in MEFPTEN-/- cells.  Both MEFPTEN+/+ and MEFPTEN-/- cell lines were treated with 
5µM Geldanamycin (GM), a Hsp90 inhibitor, for 24 hours, and total cell lysates 
were analyzed by western blot. It is not surprising that Hsp90 protein 
expression remained unchanged upon GM treatment in both cell lines, as this 
drug inhibits the ATP-ase activity of Hsp90 but not its expression. We found 
NHE-1
Hsp90










that in GM-treated MEFPTEN-/- cells, a significant decrease in NHE1 protein 
expression was observed as compared to MEFPTEN+/+ cells (Figure 7A). 
Quantitation of protein levels by densitometry further confirmed that 24 hour 
treatment with GM markedly reduced the amount of NHE1 protein by 
approximately 30% in MEFPTEN-/- cells as compared to untreated cells. In 
contrary, MEFPTEN+/+ cells displayed approximately 17% decrease in NHE1 
protein expression upon treatment with GM, to that of untreated cells (Figure 
7B). Together, these data suggests that Hsp90 activity may be required for 


















































Figure 7: Geldanamycin-induced inhibition of Heat shock protein 90 
causes downregulation of NHE1 in MEFPTEN -/- cells 
 
(A) MEFPTEN+/+ and MEFPTEN-/- cells were treated with 5µM of Geldanamycin 
(GM) or DMSO as a control and harvested 24 hrs post treatment. Cell lysates 
were subjected to western blot analysis to detect for NHE1, Hsp90 and β-
actin. Densitometric analysis of band corresponding to (B) NHE1 as described 
in (A). A representative blot from at least three independent experiments is 
shown for each protein. The value represents the mean±S.E. of three 
independent experiments, *p-value <0.05.  
 
Indeed, we have clearly shown that inhibition of Hsp90 activity causes a more 
pronounced effect on NHE1 levels in MEFPTEN-/- cells as compared to 
MEFPTEN+/+ cells. To further illustrate our findings gained with pharmacological 
inhibitors such as Geldanamycin, we used specific siRNA to downregulate 
intracellular Hsp90 in MEFPTEN+/+ and MEFPTEN-/- cells. As shown in Figure 8, 
























































150nM of siRNA. Another striking finding includes the significant 
downregulation of NHE1 protein expression in MEFPTEN-/- cells, not observed in 
wildtype cells transfected with siHsp90 (Figure 8A). Furthermore, 
densitometric assessment  showed that knockdown of Hsp90,  resulted in 
approximately 40% decrease in NHE1 expression in MEFPTEN-/- cells in 
contrast to  an estimated 15% decrease in MEFPTEN+/+ cells (Figure 8B). 
Again, this data is in agreement with our previous findings that the stability of 
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Figure 8: Silencing Hsp90 causes downregulation of NHE1 protein 
expression in both MEFPTEN+/+ and MEFPTEN-/- cells 
 
(A) MEFPTEN+/+ and MEFPTEN-/- cells were transfected with 150nM control 
siRNA (siControl) or 150nM Hsp90 siRNA (siHsp90) for 72hr. Cell lysates 
were subjected to western blot analysis to detect for NHE1, Hsp90 and β-actin 
was used as loading control. ** corresponds to a non-specific band that 
appeared due to stripping and reprobing the blot used for detection of Hsp90. 
(B) Densitometric analysis of band corresponding to NHE1 in (A). A 
























3.1.6.B Hsp90 prevents proteasome-mediated degradation of NHE1 protein in 
MEFPTEN-/- cells 
 
To elucidate the mechanism by which NHE1 is degraded in the presence of 
the Hsp90 inhibitor, Geldanamycin (GM), we used MG132 (10µM). Both 
MEFPTEN+/+ and MEFPTEN-/- cell lines were pre-treated with MG132 for 3 hours 
followed by incubation with GM. As shown earlier, the expression of Hsp90 
remained unchanged as GM blocks the function of Hsp90 and not its 
expression (Figure 9A & 9B). Consistent with the results shown earlier (Figure 
4A & 4B), incubation with MG132 alone stabilized NHE1 levels in MEFPTEN+/+ 
cells whereas no significant change was observed in MEFPTEN-/- cells. 
Interestingly, our findings demonstrate that the GM-induced down-regulation 
of NHE1 is reversed by MG132 in both cell lines (Figure 9A & 9B). Analysis by 
densitometry showed that GM alone caused a more drastic decrease in NHE1 
levels, estimating to ~30% in MEFPTEN-/- cells as compared to a decrease 
amounting to ~15% in control cells. Thus, our results indicated that 
geldanamycin-induced degradation of NHE1 is mediated by the ubiquitin-
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Figure 9: Geldanamycin causes proteasome-mediated degradation of 
NHE1 in MEFPTEN+/+ and MEFPTEN-/- cells 
 
(A) MEFPTEN+/+ and (B) MEFPTEN-/- cells was pre-treated with 5µM MG132 for 3 
hours, followed by treatment with 5µM of Geldanamycin (or DMSO as a 
control) for 24 hrs. Cell lysates were subjected to western blot analysis to 
detect for NHE1, Hsp90 and β-actin was used as loading control. 
Densitometric analysis of band corresponding to NHE1, for various treatments 
as observed in (C) & (D). A representative blot from at least two independent 

























































3.1.7 Inhibition of Hsp90 destabilizes NHE1 Protein in MEFPTEN-/- cells  
 
Based on the data so far, we have used both pharmacological and gene 
knockdown approaches to address the importance of Hsp90 in the prevention 
of NHE1 downregulation in MEFPTEN-/- cells. Therefore, these results led us to 
investigate whether Hsp90 inhibition affects the stability of NHE1 protein in 
MEFPTEN-/-   cells.  
 
Hsp90 expression was reduced in MEFPTEN-/- cells using specific siRNA and 
cells were recovered with or without CHX, to inhibit new protein synthesis. 
This was followed by subsequent collection of cell lysates at various 
timepoints thereafter and analysis by western blot (Figure 10). Hsp90 was 
efficiently silenced to approximately 60% as compared to control siRNA 
(siCo), at both 72 and 96 hours timepoints. Our data also showed that Hsp90 
siRNA induced a significant reduction in the levels of NHE1 protein in 
MEFPTEN-/- cells which was more pronounced at 96 hours post-transfection 
(Figure 10). Notably, control siRNA transfected cells containing cycloheximide 
(siCo+CHX) alone induced a reduction of NHE1 levels even at both the 72 
and 96 hour time points (Figure 10A). This finding is justified as we have 
previously shown that the estimated degradation of mature NHE1 in    
MEFPTEN-/- cells to be approximately 68 hours (Figure 3). Interestingly, NHE1 
levels were further diminished to undetectable levels in siHsp90 transfected 
cells containing CHX (siHsp90+CHX) at both 72 and 96 hour time points. 
Hence, it is noteworthy to say that the drastic loss of Hsp90 expression, may 
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have significantly contributed to the sharp decline in NHE1 levels observed in 
siHsp90 transfected cells containing CHX (siHsp90+CHX), at both 72 and 96 
hour timepoints.   
 
Taken together, these data suggest that abolishing the function of the 
molecular chaperone Hsp90 results in sharp decrease in the stability of NHE1 
protein in MEFPTEN-/- cells. Again, this stresses the crucial role of Hsp90 
complex on the stability of NHE1 protein in MEFPTEN-/- cells. Additionally, our 
results also proposes the likelihood of NHE1 being a potential client protein of 
Hsp90, however, further investigations need to be performed to confirm this.  
 
 
Figure 10: Silencing Hsp90 reduces stability of NHE1 protein in  
MEFPTEN-/-cells 
 
MEFPTEN-/- cells were transfected with control siRNA (150nM) or Hsp90 siRNA 
(150nM) for 48 hours and recovered with or without cycloheximide. Cells were 
harvested 72 or 96 hours post transfection. Cell lysates were analyzed by 


























































3.1.8 Hsp90 prevents ubiquitination of NHE1 protein in MEFPTEN-/- cells  
 
So far, the results demonstrated above strongly suggest that Hsp90 may be 
involved in preventing proteasome mediated degradation of NHE1 protein in 
MEFPTEN-/- cells. In general, prior to degradation by 26S proteasome complex, 
the protein is targeted by ubiquitinating enzymes that employ a 3-step process 
for the covalent attachment of multiple ubiquitin molecules to the desired 
protein181. Hence, we next evaluated whether Hsp90 might be conferring 
protection to NHE1 from being targeted for ubiquitination. Geldanamycin 
treated or untreated MEFPTEN-/- cells were immunoprecipitated with an anti-
NHE1 or control IgG antibody and immunoprecipitates were analysed by 
western blot.  The presence of ubiquitination was validated by probing with 
anti-P4D1 antibody that recognized mono and polyubiquitination.  
 
MG132 was used as a control as it not only inhibits proteasome degradation 
pathway but causes the accumulation of ubiquitinated species resulting in an 
intense smear. Hence, MG132 treatment resulted in enhanced detection of 
the higher-molecular-weight species (Ub-NHE1) compared to untreated 
immunoprecipitate (Figure 11A, compare 2 and 4). Interesingly, we found an 
increase in ubiquitination of NHE1 detected as higher molecular weight 
species (Ub-NHE1) (Figure 11A, compare lanes 2 and 3), accompanied by a 
significant reduction in the level of NHE1 protein upon GM treatment, as 
compared to the control (Figure 11B, compare lanes 1 and 2). Together, these 
data suggest that the GM-induced decrease in NHE1 protein levels may be 
due to the abrogation of Hsp90 function resulting in ubiquitin-mediated 
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proteasome degradation of NHE1 protein. Also, it is noteworthy to say that 
Hsp90 may also be involved in preventing NHE1 ubiquitination and its 
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Figure 11: Hsp90 inhibition results in ubiquitination of NHE1  
 
MEFPTEN-/- cells grown in DMEM/10%FBS and were treated with 5µM of 
geldanamycin (GM) or DMSO as a control for 24 hrs. Cell lysates were 
prepared and immunoprecipitated with anti-NHE1 or control IgG antibody. 
(A)The precipitates and (B) inputs were analyzed by western blot using 
antibody against ubiquitin (P4D1), NHE1. A representative blot from two 
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3.2 Akt is responsible for bringing Hsp90 to the membrane and 
increasing NHE1 stability in MEFPTEN-/- cells  
 
3.2.1 Hyperphosphorylation of Akt correlates with an increased level of 
NHE1 in MEFPTEN-/- cells  
 
3.2.1.A MEFPTEN-/- cells display hyperphosphorylation of Akt and increased 
NHE1 protein expression as compared to MEFPTEN+/+ cells 
 
Akt, a critical player involved in PI3K signalling, requires activation at the 
Serine 473 and Threonine 308 sites by the mTORC2 complex and PDK1, 
respectively, to mediate downstream events that contribute to the growth, 
proliferation and differentiation of cells93,182. The tumour suppressor, PTEN, 
negatively regulates PI3K/Akt pathway through dephosphorylation of PIP3. 
Inactivation of PTEN in human cancer, has been shown to result in the 
aberrant hyperactivation of Akt183,184. As shown in Section 3.1.1, MEFPTEN-/- 
cells appeared to display increased expression of NHE1 as compared to 
MEFPTEN+/+ cells. Thus, in this study, we were keen to investigate whether a 
correlation exists between the hyperphosphorylation of Akt and increased 
expression of NHE1 in MEFPTEN-/- cells     
 
MEFPTEN+/+ and MEFPTEN-/- cells growing in 10% fetal bovine serum (FBS) were 
analysed by western blot analysis for the expression of phosphorylated Akt 
(Figure 12A). MEFPTEN+/+ cells displayed a lower phosphorylation level of Akt 
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Serine 473 and Threonine 308 sites compared to MEFPTEN-/- cells that showed 
a distinct hyperphosphorylation of Akt. Notably, we reason that the lack of Akt 
phosphorylation at the Threonine 308 site observed in MEFPTEN+/+ cells was 
too low to be detected by western blot. 
 
Previous reports have identified Glycogen Synthase Kinase-3 beta (GSK3β) 
as a downstream target of Akt, which is inhibited by direct phosphorylation at 
the Serine 9 site of GSK3β185. In line with the results displaying 
hyperphosphorylation of Akt in MEFPTEN-/- cells, the phosphorylation levels on 
GSK3β at the Serine 9 site was enhanced as compared to MEFPTEN+/+  cells 
(Figure 12A). Hence, this further confirms the increased in vivo kinase activity 
of Akt present in MEFPTEN-/- cells.  
 
In addition, MEFPTEN+/+ and MEFPTEN-/- cell lysates were collected and 
examined by immunoblot to analyse the distribution of NHE1 and PTEN 
(Figure 12B). As a control for our analysis, PTEN was only detected in 
MEFPTEN+/+ and not in MEFPTEN-/- cells. The mature form of NHE1 protein 
(90∼110 kDa, highly glycosylated form)175 appeared to be significantly 
increased in  MEFPTEN-/- cells as compared to control cells. Taken together, 
our results show a correlation between the hyperphosphorylation of Akt and 











Figure 12: Hyperphosphorylation of Akt correlates with increased NHE1 
protein expression in MEFPTEN-/- cells compared to MEFPTEN+/+ cells.  
 
(A) MEFPTEN+/+ and MEFPTEN-/- cells were grown in DMEM/10% FBS for 24 
hours and assessed by western blot analysis for Akt phosphorylation at Thr 
308 (p-Akt Thr 308) and Ser 473 (p-Akt Ser 473) sites and total Akt.  
Phosphorylation levels of GSK3β at Serine 9 (p- GSK3β Ser 9) and total 
GSK3β was also detected. (B) NHE1 and PTEN expression levels were 
assessed. β-Actin was used as loading control. A representative blot from at 



















3.2.1.B Inhibition of Akt downregulates  NHE1 protein expression but not 
mRNA levels in MEFPTEN-/- cells  
 
Another possible way of addressing the role of Akt in the regulation of NHE1 is 
by interfering with its endogenous function using specific Akt-siRNA. Prior to 
the Akt knockdown approach, we first identified the prevalence of different Akt 
isoforms in both MEFPTEN+/+ and MEFPTEN-/- cells (Figure 13). Interestingly, our 
data confirmed that the Akt isoform 1 was abundant in both cell lines whereas 
Akt isoforms 2 and 3 were barely detectable by immunoblot. 
 
 
Figure 13: Akt 1 isoform is detectable in MEFPTEN-/- cells  
 
MEFPTEN+/+ and MEFPTEN-/- cells were grown in DMEM/10% FBS for 24 hours 
and total cell lysates were collected. Triplicate sets of lysates (WT & KO) were 
loaded analysed by western blot on the same gel to detect (A) Akt isoform 1, 
(B) 2 and (C) 3. β-actin was used as a loading control. A representative blot 




Hence,   MEFPTEN-/- cells were transfected with specific Akt1 siRNA to examine 
its effect on NHE1 expression (Figure 14A). Immunoblot analysis indicated 
50kDa
37kDa
WT        KO                     WT     KO                        WT      KO 
β-actin








that the decrease in endogenous Akt levels to 80% that of control, 48 hrs post 
transfection. Also, this reduction in Akt expression was accompanied by a 
marked decline in NHE1 protein levels. When compared to the control siRNA-
transfected cells, NHE1 protein levels were reduced by approximately 22% 
upon silencing Akt in MEFPTEN-/- cells (Figure 14B). Together, these data 
provide compelling evidence that Akt may have a significant role in regulating 
the expression of NHE1 in MEFPTEN-/- cells. 
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Figure 14: Silencing Akt induces downregulation of NHE1 protein 
expression in MEFPTEN-/- cells. 
 
(A) MEFPTEN-/- cells were transfected with control siRNA (siCo) or Akt siRNA 
(siAKT). Cell lysates were harvested 48hr post transfection and subjected to 
western blot analysis to detect for NHE1 and total Akt. β-actin was used as 
loading control. A representative blot from at least three independent 
experiments is shown for each protein. For densitometric analyses shown in 
(B), the expression level of NHE1 was normalised to β-actin. The change in 
NHE1 level was shown as a fold difference relative to control siRNA. The data 





Next, we assessed whether siRNA-mediated knockdown of Akt had any effect 
on NHE1 mRNA levels in MEFPTEN-/- cells. We have previously shown that the 
silencing of Akt in MEFPTEN-/- cells results in a concomitant decrease in the 
amounts of NHE1 protein (Figure 14). However, 48 hour post transfection with 











































levels (Figure 15). Together, this confirms that Akt’s role in the regulation of 
NHE1 protein expression is not due to the regulation of NHE1 transcription.  
 
 
Figure 15: Silencing Akt shows no effect on NHE1 transcription in 
MEFPTEN-/- cells 
 
MEFPTEN-/- cells were transfected with control siRNA (siCo) or Akt siRNA 
(siAkt). Total RNA was extracted 48hr post transfection. cDNA were 
generated as described in Materials and methods. NHE1 mRNA expression 
were quantified by Taqman real-time PCR, normalized to endogenous control 
(18S RNA). Relative NHE1 mRNA expression is expressed as a fold 
difference relative to control siRNA. The data represent the mean±S.E. from 












































3.2.1.C Preventing Akt from binding to PIP3 downregulates NHE1 protein 
expression in MEFPTEN-/- cells  
 
Having established a correlation between the Akt and the increase in NHE1 
expression in MEFPTEN-/- cells, we next asked if the constitutive activation of 
Akt plays a role in regulating NHE1 protein levels. One possible way to 
address this is to utilize specific inhibitors of the PI3K/Akt pathway and 
observe its effects on NHE1 expression. LY294002, a derivative of the 
flavanoid quercetin, has been shown to have an inhibitory profile across 
different classes of PI3-Kinases186. In particular, LY294002 inhibits PI3K 
activity by competing for its ATP binding site, resulting in decreased PIP3 
levels187. Hence, the time-course effect of LY294002 on both MEFPTEN+/+ and 
MEFPTEN-/- cells was examined by immunoblot analysis. Figure 16 illustrates 
the efficacy of LY294002 as phosphorylated Akt is decreased to an almost 
undetectable level within 2 hours in both MEFPTEN+/+ and MEFPTEN-/- cells. In 
particular, Akt phosphorylation  at both Ser 473 and Thr 308 sites was rapidly 
decreased (< 0.5hr) in MEFPTEN+/+ cells (Figure 16A) whereas MEFPTEN-/- cells 
displayed a delay in Akt dephosphorylation (Figure 16B). Furthermore, the 
dephosphorylation of Akt in MEFPTEN-/- cells appeared to correlate with the 
downregulation of NHE1 protein expression, an observation not detectable in 
MEFPTEN+/+ cells. Therefore, this data supports the hypothesis that Akt is 
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Figure 16: LY294002 induces downregulation of NHE1 protein 
expression in MEFPTEN-/- cells 
 
(A) MEFPTEN+/+ and (B) MEFPTEN-/- cells were treated with 25µM LY294002 and 
were harvested between 0-8hrs. Total cell lysates were assessed by western 
blot analysis to detect NHE1, Akt phosphorylation at Thr308, Ser473 and total 
Akt. β-actin was used as a loading control. A representative blot from at least 





























Having established that Akt activation status correlates with NHE1 protein 
expression in MEFPTEN-/- cells using LY294002 drug treatment, we next asked 
whether an alternative PI3-Kinase inhibitor could modulate PIP3 levels and 
reproduce the same effects seen in Figure 3. Hence, Wortmannin, a naturally 
occurring metabolite derived from Penicillium funiculosum188, was used to 
block Akt activation in both MEFPTEN+/+ and MEFPTEN-/- cells (Figure 17). 
Similar to LY294002 treatment (Figure 16), Akt phosphorylation at the Ser 473 
site attenuated rapidly in less than an hour in MEFPTEN+/+ cells whereas 
MEFPTEN-/- cells exhibited a delay in AKT dephosphorylation (Figure 17A & 
17B). Moreover, the inhibition of Akt correlated with the decrease in NHE1 
protein expression in MEFPTEN-/- cells, a phenomenon not observed in 
MEFPTEN+/+ cells. Thus, our data supports once again that Akt may have an 



















Figure 17: Wortmannin induces downregulation of NHE1 protein 
expression in MEFPTEN-/- cells 
 
(A) MEFPTEN+/+ and (B) MEFPTEN-/- cells were treated with 50nM Wortmannin 
and were harvested between 0-8hrs. Total cell lysates were assessed by 
western blot analysis to detect NHE1, Akt phosphorylation at Ser 473 (p-Akt 
S73) and total Akt. β-actin was used as a loading control. A representative blot 
from at least two independent experiments is shown for each of the gels 

























Upon stimulation by various agonists, PI-3K activation results in rapid 
translocation of Akt to the plasma membrane which is necessary for its full 
activation by mTORC2 complex and PDK1189,190. Previous studies have 
reported that the small molecule Akt/protein kinase B inhibitor, API-1, binds 
specifically to the pleckstrin homology (PH) domain of Akt and blocks its 
membrane translocation191. Therefore, having shown that PI3K inhibitors 
(LY294002 and Wortmannin) have a pronounced effect on NHE1 protein 
expression in MEFPTEN-/- cells (Figure 16 & 17), we next questioned whether a 
specific Akt inhibitor, API-1, would reproduce a similar effect on NHE1 levels 
in MEFPTEN-/- cells. API-1 induced abrogation of Akt kinase activity was 
confirmed through the dephosphorylation of Akt at the Ser 473 site (Figure 
18A). Indeed, western blot analysis showed that API-1 induced a marked 
decrease in NHE1 levels. Moreover, quantitation by densitometry (Figure 18B) 
showed that the reduction in NHE1 levels amounts to approximately 54% in 
API-1 treated MEFPTEN-/- cells as compared to untreated cells.  
 
The lack of the negative regulator PTEN, results in elevated levels of PIP3 
that facilitates increased Akt binding and kinase activation192. Hence, by 
diminishing the available PIP3 levels by utilizing two structurally dissimilar 
inhibitors, LY294002 (25μM) and Wortmannin (50nM) that target PI3-Kinase 
and preventing the membrane recruitment of Akt using API-1, NHE1 protein 
expression is downregulated in MEFPTEN-/- cells. Taken together, we evidently 
demonstrate that rather than its activity, it may be Akt itself that has a direct 
effect on NHE1 protein expression. Moreover, this data indicates that the 
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recruitment of Akt at the membrane may be crucial in regulating the 






























Figure 18: API-1 induces downregulation of NHE1 protein expression in 
MEFPTEN-/- cells 
 
(A) MEFPTEN-/- cells were treated with API-1 (25µM) for 24hrs. Whole cell 
lysates were assessed by western blot to detect NHE1, Akt Ser473 and total 
Akt levels. β-actin was used as loading control. Results shown is 
representative from at least three independent experiments. For densitometric 
analysis shown in (B), the expression level of NHE1 was normalised to β-
actin. The change in NHE1 level was shown as a fold difference relative to 
control cells. The data represents the mean±S.E. from three independent 



























































3.2.1.D Inhibition of Akt activation does not affect NHE-1 transcription in 
MEFPTEN-/- cells 
 
Having shown that dephosphorylation of Akt correlates with the 
downregulation of NHE1 protein expression levels in LY294002–treated 
MEFPTEN-/- cells (Figure 16), we then asked if the same drug treatment had an 
effect on NHE1 at the transcriptional level. To confirm this, we assessed 
NHE1 mRNA levels upon treatment with LY294002 using Real-Time PCR 
analysis. Our data demonstrated no correlation between NHE1 mRNA levels 
in MEFPTEN+/+ cells (Figure 19A) and its protein expression levels (Figure 16A). 
In particular, MEFPTEN-/- cells displayed no significant NHE1 mRNA (Figure 
19B) downregulation at timepoints that demonstrated a decrease in NHE1 
protein expression (Figure 16B). Together, our findings suggest that Akt-
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Figure 19: LY294002 has no significant effect on NHE1 transcription in 
MEFPTEN-/- cells 
 
(A) MEFPTEN+/+ and (B) MEFPTEN-/- cells were treated with LY294002 (25µM) 
before total RNA was extracted at various timepoints (0-8 hrs) and cDNA was 
generated as described in Materials and Methods. NHE1 mRNA expression 
was quantified by Taqman real-time PCR, normalized to endogenous control 
(18S RNA). Relative NHE1 mRNA expression is expressed as a fold 
difference relative to untreated control (0hr). The data represents the 
mean±S.E. from three independent experiments done in duplicates, * p < 
























3.2.2 NHE1 binds to Akt in MEFPTEN-/- cells 
 
The cytoplasmic tail region of NHE1 has been shown to act as an anchor for 
various proteins to mediate signalling pathways and to regulate other cellular 
functions193. Indeed, Wu and colleagues74 have previously proposed that one 
mechanism through which NHE1 promotes cell survival is by acting as a 
scaffold for the recruitment of a signalplex involving ezrin/radixin/moesin 
(ERM), eventuating in the activation of an Akt-dependent cell survival pathway 
in renal tubular cells. Additionally, the co-localization of NHE1, ERM, and Akt 
has also been shown to be apparent in migrating fibroblasts194. Having 
established that Akt regulates NHE1 protein expression in MEFPTEN-/- cells, we 
next hypothesized that Akt mediated regulation of NHE1 protein may occur 
through physical interaction with each other and this may be a crucial factor 
contributing towards cell survival in MEFPTEN-/- cells. Thus, to assess the 
interaction between NHE1 and Akt in MEFPTEN-/- cells, cell lysates were 
immunoprecipitated with an anti-NHE1 or control IgG antibody. The resulting 
immunoprecipitates and inputs were then assessed by western blot analysis 
(Figure 20). Interestingly, our data revealed that enhanced binding of NHE1 to 
Akt was observed in MEFPTEN-/- cells. However, a less intense co-precipitated 
Akt band was detected in MEFPTEN+/+ cells. Thus, it may be likely that at basal 
conditions, NHE1 and Akt may have transient interactions, whereas their 
interaction is enhanced in MEFPTEN-/- cells. Together, these findings support 
that Akt-mediated regulation of NHE1 expression in MEFPTEN-/- cells occurs in 





Figure 20: NHE1 interacts with Akt in MEFPTEN-/- cells 
 
MEFPTEN-/- cells grown in DMEM/10%FBS for 24 hours. Cell lysates were 
subjected to membrane-cytosol fractionation. The membrane fraction was 
then used and immunoprecipitated with anti-NHE1 or control IgG antibody. 
The precipitates and input were analyzed by western blot using antibody 




















3.2.3 Akt is a client protein of Hsp90  
 
3.2.3.A. Akt forms a complex with Hsp90 in MEFPTEN-/- cells but not in 
MEFPTEN+/+ cells 
 
Akt hyperactivation is one possible way through which the pro-survival kinase 
has been shown to foster tumorigenesis182. A recent study reported that the 
Ser 473 phosphorylation site on Akt makes it prone to instability as it induces 
a Lys-48-linked polyubiquitination of Akt leading to its rapid proteasomal 
degradation195. Therefore, chaperone proteins that stabilize Akt may be 
abundant in tumour cells that inherit Akt hyperphosphorylation. Interestingly, 
Sato and colleagues167 have previously shown that Hsp90 plays a key role in 
stabilizing Akt activation through Akt-Hsp90 binding in vivo and thereby 
prevents cells from undergoing apoptosis  induced by PP2A-mediated 
dephosphorylation of Akt. 
 
To decipher whether MEFPTEN-/- cells adopts a similar mechanism whereby Akt 
is stabilized by Hsp90, we immunoprecipitated cell lysates from both 
MEFPTEN+/+ and MEFPTEN-/- cell lines with either anti-Akt or IgG antibody and 
assessed by western blot for the presence of Hsp90 (Figure 21A). 
Surprisingly, our data identified a distinct Akt-Hsp90 complex present in 
MEFPTEN-/- cells, which was absent in MEFPTEN+/+ cells. This data strongly 
suggests that Hsp90 may be crucial in stabilizing Akt in MEFPTEN-/- cells. 
Taken together, based on our findings, it is likely that Akt exists in two different 
complexes, NHE1-Akt and Akt-Hsp90 independently in MEFPTEN-/- whereas 
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MEFPTEN+/+ cells only incurs a minimal NHE1-Akt interaction. A schematic 
representation of the association between NHE1, Akt or Hsp90 that exist in 






Figure 21: Akt forms a complex with Hsp90 in MEFPTEN-/- cells but not in 
MEFPTEN+/+ cells.  
 
(A) MEFPTEN+/+ and MEFPTEN-/- cells grown in 10%FBS and cell lysates were 
prepared and immunoprecipitated with anti-Akt antibody. The precipitates and 
lysates were analysed by western blot using antibody against Akt and Hsp90. 
(B) Schematic diagram representing the proposed interaction between NHE1, 





















3.2.3.B Akt-Hsp90 complex shuttles between membrane and cytosol as a 
complex in MEFPTEN-/- cells 
 
At a basal level, Akt primarily resides in the cytosol. However, upon 
stimulation by growth factors, activated PI3K generates phosphatidylinositol 
3,4,5-triphosphate (PIP3), which is a target of Akt. The interaction between Akt 
pleckstrin homology (PH) domain and PIP3 that is present on the inner leaflet 
of the plasma membrane eventuates in a conformational change resulting in 
its full kinase activation at both the Ser 473 and Thr308 sites by mTORC2 
complex and PDK1 respectively. This is followed by the translocation of 
activated Akt into the cytosol to phosphorylate and activate its downstream 
targets196. On the other hand, relocalization of a fully active kinase to the 
cytosol, is often a target for phosphatases. For example, the enzyme PP2A 
preferentially targets the dephosphorylation of Akt at the Thr308 sites197. A 
number of reports proposed that Hsp90 interaction with Akt prevents PP2A 
mediated dephosphorylation, thus confering increased stability to Akt167,198-200.  
 
Having shown that the Akt-Hsp90 complex only exist in MEFPTEN-/- cells and 
not in control cells, we next sought to decipher whether Akt translocation to 
the membrane occurs in complex with Hsp90 or is released from Hsp90 prior 
to membrane association. To address this, we performed Akt pulldown in 
MEFPTEN-/- cells lysates that were subjected to subcellular fractionation 
(membrane-cytosol). Immunoprecipitates were analyzed by western blot and 
probed for Hsp90 (Figure 22A). Interestingly, we found that Akt-Hsp90 
complex does predominantly exist in the cytosol but can be detected at the 
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plasma membrane. Moreover, this data suggests that may be likely Akt 
shuttles to the membrane in complex with Hsp90 during Akt kinase activation 
in MEFPTEN-/- cells.  
 


































Figure 22: Subcellular distribution of Hsp90/Akt complex in MEFPTEN-/- 
cells 
 
MEFPTEN-/- cells grown in DMEM/10%FBS were subjected to membrane-
cytosol fractionation. Both membrane and cytosol fractions were 
immunoprecipitated with anti-Akt antibody or control IgG. (A) The 
immunoprecipitates (IP) and (B) inputs (In) were analyzed by western blot 
using antibody against Akt and Hsp90. The inputs (In) were also analyzed on 
a separate gel to detect VDAC (membrane control) and Cu/ZnSOD (cytosolic 
control). The immunoblots are representative of two experiments. (C) 
Schematic diagram representing the subcellular distribution of Akt-Hsp90 
















3.2.3.C Akt recruits Hsp90 to the membrane in MEFPTEN-/- cells 
 
Although the molecular chaperone, Hsp90, is primarily a cytosolic protein, our 
data shows that it is complexed with Akt and is detectable at the plasma 
membrane in the MEFPTEN-/- cells (Figure 22). Thus, we next hypothesized that 
Akt may be responsible in recruiting Hsp90 to the membrane. To examine this 
possibility, MEFPTEN-/- cells was incubated with the specific Akt inhibitor API-1 
for 24 hours. Cell lysates were subjected to membrane-cytosol fractionation 
and fractionated samples were analysed by western blot (Figure 23).   
 
API-1 is an inhibitor which specifically binds to Akt and prevents its 
association with the PH domain on PIP3. In agreement with this, a sharp 
decline in total Akt at the plasma membrane was found in API-1 treated 
MEFPTEN-/- cells. Interestingly, we also observed that API-1 induced a 
significant reduction in the Hsp90 level which correlated with the decrease in 
total Akt at the membrane (Figure 23). These results support that in the 
absence of Akt at the membrane, the levels of Hsp90 decline rapidly, 
suggesting that Akt may be involved in the recruitment of Hsp90 to the 








Figure 23: Akt recruits Hsp90 to the membrane in MEFPTEN-/- cells 
 
MEFPTEN-/- cells were grown in 10%FBS and treated with 25μM API-1 (or 
DMSO as a control) for 24 hours. Cell lysates were subjected to membrane/ 
cytosol fractionation. Both fractions were analyzed by western blot using 
antibody against T-Akt and Hsp90. VDAC was used as a membrane fraction 
control and Cu/ZnSOD as a cytosolic control. The immunoblots are 



























3.2.3.D Inhibition of Hsp90 mediates degradation of Akt in MEFPTEN+/+ and 
MEFPTEN-/- cells 
 
Increasing evidence has been shown to emphasize the importance of Hsp90 
in the stability of Akt in various cancer cell lines200. Hence, we investigated the 
role of Hsp90 bound Akt in both MEFPTEN+/+ and MEFPTEN-/- cell lines. Previous 
studies have reported that in the presence of anasamycin antibiotics such as 
Geldanamycin (GM), Hsp90 clients proteins are degraded through the 
ubiquitin proteasome pathway201. At 5 μM of GM, the total Akt expression 
levels was drastically diminished in MEFPTEN-/- cells as compared to its 
wildtype counterpart (Figure 24A). Densitometric analysis further confirmed 
that Akt expression levels were reduced to approximately 63% as compared 
to untreated cells in MEFPTEN-/- cell line (Figure 24B). However, an estimated 
35% decrease to that of control cells was observed in MEFPTEN+/+ cells (Figure 
24B). This strongly suggests that Hsp90 activity may play a significant role to 
















Figure 24: Inhibition of Hsp90 mediates degradation of Akt in MEFPTEN+/+ 
and MEFPTEN-/- cells 
 
(A) MEFPTEN+/+ and MEFPTEN-/- cells were treated with 5µM of Geldanamycin 
for 24 hrs. Cell lysates were subjected to western blot analysis to detect for 
total Akt, Hsp90 and β-actin was used as loading control. (B) Densitometric 
analysis of band corresponding to Total Akt from figure (A). The immunoblots 
are representative of three experiments.  
















































































As a step further, we evaluated the mechanism by which Akt is degraded 
upon Hsp90 inhibition. Studies have shown that the Ubiquitin Proteasome 
Pathway (UPP) is one of the mechanisms that the cell employs to regulate 
turnover of most short- and long-lived proteins45. Both cell lines were pre-
treated with MG132 for 3 hours prior to the addition of GM for another 24 
hours and cell lysates were analysed by immunoblot analysis (Figure 25). As 
expected, GM alone caused a sharp decrease in total Akt in MEFPTEN-/- cell as 
compared to wildtype cells. Surprisingly, the recovery of total Akt expression 
in the presence of MG132 and GM was not observed in both cell lines (Figure 
25A and 25B). It may be possible that the inhibition of proteasome may induce 
aggresome formation resulting in accumulation of Akt in perinuclear vesicles 
which may not be detectable in whole cell lysates but in insoluble fractions166. 
Thus, cell lysates were prepared in a similar manner as in Figure 25, and 
soluble and insoluble fractionation was performed and analyzed by western 

















Figure 25: Geldanamycin induces proteasome- mediated degradation of 
Akt in MEFPTEN+/+ and MEFPTEN-/- cells 
 
(A) MEFPTEN+/+ and (B) MEFPTEN-/- cells were pre-treated with 5µM MG132 for 
3 hours, followed by treatment with 5µM of Geldanamycin for 24 hrs. Cell 
lysates were subjected to western blot analysis to detect Total Akt, Hsp90 and 
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Figure 26: Total Akt accumulates in insoluble fractions in the presence 
of Geldanamycin and MG132 in MEFPTEN+/+ and MEFPTEN-/- cells 
 
(A) MEFPTEN+/+ and (B) MEFPTEN-/- cells were pre-treated with 5µM MG132 for 
3 hours, followed by treatment with 5µM of Geldanamycin for 24 hrs. Cell 
lysates were subjected to membrane/cytosol fractionation and analysed by 
western blot to detect total Akt and CuZnSOD (soluble fraction control). The 
immunoblots are representative of two experiments. (C) Schematic diagram 
highlighting the role of Akt-Hsp90 complex. Hsp90 protect 
hyperphosphorylated Akt and prevents proteasome-mediated degradation of 
Akt in MEFPTEN-/- cells. Blots were exposed to film for shot intervals (short 
exposure) or long (long exposure) intervals. 
 
 
Our data clearly demonstrated that in the cells treated with both MG132 and 
GM, total Akt was diminished in soluble fractions and recovered in insoluble 
fractions (Figure 26). Taken together, our observations conclude that indeed 
Hsp90 is crucial in maintaining the stability of Akt and abrogation of Hsp90 










3.2.4 NHE1 forms a complex with Hsp90 and Akt in MEFPTEN-/- cells  
 
So far, our data has demonstrated that the inhibition of Akt or Hsp90 promotes 
the downregulation of NHE1 protein expression. This prompted us to check 
whether Akt, Hsp90 and NHE1 form a complex in MEFPTEN-/- cells. Thus, 
MEFPTEN-/- cells were transfected with control siRNA (siCo) or Hsp90 siRNA 
(siHsp90) for 72 hours prior to immunoprecipitation with anti-NHE1 antibody or 
control IgG (Figure 27). The inputs clearly indicate the efficient silencing of 
Hsp90 to approximately 80% to that of control siRNA (Figure 27A). As a 
control, normal rabbit IgG did not precipitate Akt or Hsp90 or NHE1 (Figure 
27B). An important observation was that immunoprecipitates transfected with 
control siRNA (siCo) displayed the strong tripartite complex formation between 
NHE1, Hsp90 and Akt. However, the knockdown of Hsp90 by siRNA 
(siHsp90) reduced the amounts of NHE1 pulled down but not as drastic as the 
effect seen in whole cell lysates (Figure 8). This may be due to the anti-NHE1 
antibody in excess, resulting in maximization or saturation of the signal. In 
addition, only a slight decrease in total Akt pulled down is observed upon 
silencing Hsp90. We reason that silencing Hsp90 may have decreased the 
Akt-Hsp90 complexes that translocate to the membrane and decreased the 
NHE1-Hsp90 complex at the membrane. However, NHE1-Akt interaction at 
the membrane is not affected and this may explain the lack of difference in 
total Akt pulled down by NHE1, in immunoprecipitates containing siHsp90 










Figure 27: Hsp90 binds to NHE1 independent from Akt 
 
MEFPTEN-/- cells were transfected with siRNA for Hsp90 (siHsp90) or negative 
control (siCo). Cells were harvested 72 hours post transfection and 
immunoprecipitation was performed with antibody for Akt or control IgG. (A) 
Immunoprecipitates and (B) inputs were analysed by Western blot on the 
same gel to detect NHE1, Akt or Hsp90. The immunoblots are representative 









































Immunoprecipitates were prepared in a similar manner whereby MEFPTEN-/- 
cells were transfected with control siRNA (siCo) or Akt siRNA (siAkt) for 72 
hours prior to immunoprecipitation with anti-NHE1 antibody or control IgG 
(Figure 28). Accordingly, as observed in the inputs, Akt was silenced 
efficiently to approximately 80% to that of control siRNA (Figure 28A).  
 
Our data demonstrated the existence of NHE1-Akt-Hsp90 tripartite complex   
detected in lanes that contain control siRNA (siCo). Moreover, the knockdown 
of Akt by siRNA (siAkt) reduced the amounts of NHE1 pulled down (Figure 
28B). In addition, only a slight decrease in total Hsp90 pulled down is 
observed upon silencing Akt. We reason that silencing Hsp90 may have 
decreased the Akt-Hsp90 complexes that translocate to the membrane and 
NHE1-Akt interaction at the membrane. However, NHE1-Hsp90 interaction at 
the membrane is not affected and this may explain the lack of difference in 
total Hsp90 pulled down by NHE1, in immunoprecipitates containing siAkt 
(Figure 28B).   
 
Taken together, our findings suggest that Akt, Hsp90 and NHE1 may exist as 
a stable complex at the membrane in MEFPTEN-/- cells. However, knockdown of 
either Akt or Hsp90 expression results in the NHE1-Akt-Hsp90 complex 







28A)                                                                         
 
28B) 
                   
Figure 28: Silencing Akt does not affect NHE1/Hsp90 complex 
significantly 
 
MEFPTEN-/- cells were transfected with siRNA for Hsp90 (siAkt) or negative 
control (siCo). Cells were harvested 72 hours post transfection and 
immunoprecipitation was performed with antibody for Akt or control IgG. (A) 
Immunoprecipitates and (B) inputs were analyzed by Western blot on the 
same gel to detect NHE1, Akt and Hsp90. The immunoblots are 




We have previously established that Hsp90 is complexed with Akt and is 
detectable at the plasma membrane in the MEFPTEN-/- cells (Figure 22). 














Hsp90 to the membrane. Another way of demonstrating the effect of Akt-
Hsp90 complex on NHE1 expression in MEFPTEN-/- cells is to prevent the 
membrane recruitment of Akt mediated by API-1. Hence, MEFPTEN-/- cells were 
incubated with the specific Akt inhibitor API-1 for 24 hours. Cell lysates were 
subjected to membrane-cytosol fractionation and fractionated samples were 
analysed by western blot (Figure 29).   
 
API-1 is an inhibitor which specifically binds to Akt and prevents its 
association with the PH domain on PIP3. In agreement with this, a sharp 
decline in total Akt at the plasma membrane was found in API-1 treated 
MEFPTEN-/- cells. The decrease in Akt was accompanied with a decline in 
Hsp90 levels at the membrane. Interestingly, we observed API-1 mediated 
inhibition of Akt at the plasma membrane led to the drastic loss of NHE1 
protein to an undetectable level at the membrane. Taken together, these 
results support that in the absence of Akt-Hsp90 complex at the membrane, 
the levels of NHE1 decline rapidly.  A schematic representation of the tripartite 




















Figure 29: Akt recruits Hsp90 to the membrane in MEFPTEN-/- cells 
 
(A) MEFPTEN-/- cells were grown in 10%FBS and treated with API-1 for 24 
hours. Cell lysates were subjected to membrane/ cytosol fractionation. Both 
fractions were analyzed by western blot using antibody against NHE1,T-Akt 
and Hsp90. VDAC was used as a membrane fraction control and Cu/ZnSOD 
as a cytosolic control. ** corresponds to a non-specific band that appeared 
due to stripping and reprobing the blot used for detection of Hsp90. The 
immunoblots are representative of two experiments. (B) Schematic diagram 






























Based on the data so far, we have used both pharmacological and gene 
knockdown approaches to address the importance of Hsp90 in the prevention 
of NHE1 downregulation in MEFPTEN-/- cells. Therefore, these results led us to 
investigate whether Hsp90 inhibition affects the stability of NHE1 protein in 
MEFPTEN-/-   cells.  
 
Hsp90 expression was reduced in MEFPTEN-/- cells using specific siRNA and 
cells were recovered with or without CHX, to inhibit new protein synthesis. 
This was followed by subsequent collection of cell lysates at various 
timepoints thereafter.  As shown in Figure 30A, Hsp90 silencing was reduced 
to approximately 70% to that of control at both 72 and 96 hours timepoints. 
However, Hsp90 expression in control siRNA -transfected cells treated with 
CHX remains unaffected.  
 
Similar to previous findings in Figure 8, our data also showed that Hsp90 
siRNA induced a significant reduction in the levels of NHE1 protein in 
MEFPTEN-/- cells which was more pronounced at 96 hours post-transfection 
(Figure 30A). Interestingly, control siRNA transfected cells containing 
cycloheximide (siCo+CHX) alone induced a reduction of NHE1 levels even at 
both the 72 and 96 hour time points (Figure 30A). This finding is justified as 
we have previously shown that the half-life of mature NHE1 in MEFPTEN-/- cells 
to be approximately 68 hours (Figure 3B). Also, we demonstrated earlier that 
NHE1 forms a complex with both Akt and Hsp90 in MEFPTEN-/- cells (Figure 27 
& 28). Interestingly, the drastic loss of total Akt and Hsp90 expression 
observed in siHsp90 transfected cells containing CHX (siHsp90+CHX), 
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resulted in the significant destabilization of NHE1 protein at both 72 and 96 
hour timepoints (Figure 30).   
 
Taken together, these data suggest that abolishing the function of the 
molecular chaperone Hsp90 together with the downregulation of total Akt 
results in the sharp decline in the stability of NHE1 protein in MEFPTEN-/- cells. 
Again, this stresses the crucial role of Hsp90-Akt complex on the stability of 














Figure 30: Silencing Hsp90 reduces half-life of NHE1 protein in MEFPTEN-/-
cells 
 
A) MEFPTEN-/- cells were transfected with control siRNA (150nM) or Hsp90 
siRNA (150nM) for 48 hours and recovered with or without cycloheximide.  
Cells were harvested 72 or 96 hours post transfection. Cell lysates were 
analyzed by Western blot to detect NHE1, total Akt and Hsp90. Anti- actin was 
used as a loading control. A representative blot from at least two independent 












































































3.2.5 Hsp90-Akt downregulation affects cell survival in MEFPTEN-/- cells  
 
Several reports have implicated NHE1 in cell survival74,193. In our study, we 
observed massive cell death in GM-treated MEFPTEN-/- cells as compared to 
control cells (Figure 31). We have previously shown in Section 3.1.6, that GM 
induces significant downregulation of NHE1 protein expression. In addition, in 
Section 3.2.3.D, we showed that abrogation of Hsp90 function significantly 
downregulates Akt expression. Taken together, our data suggest that both 
inhibition of Hsp90 and the significant loss of Akt result in the drastic loss of 
NHE1 levels. Moreover, NHE1 has been shown to be linked to cell survival34. 
Hence, it may be likely that GM may have promoted the dissociation of the 
NHE1-Akt-Hsp90 complex resulting in the significant increase in cell death 
observed in MEFPTEN-/- cells as compared to its wildtype counterpart. Thus, our 
data suggest that NHE1-Akt-Hsp90 complex may have an impact on cell 




Figure 31: Geldanamycin-induced inhibition of Heat shock protein 90 
causes increased cell death in MEFPTEN-/- cells as compared to MEFPTEN+/+ 
cells 
 
MEFPTEN+/+ and MEFPTEN-/- cells were treated with 5µM of Geldanamycin (GM) 
or DMSO as a control and harvested 24 hrs post treatment. Cell lysates were 
subjected to western blot analysis to detect for NHE1, Hsp90 and β-actin. 
Microscopic images of 24 hours post-GM treated and untreated MEFPTEN+/+ 
and MEFPTEN-/- cells observed under a phase contrast microscope (10X 
magnification). Images are representative of three experiments. 
 
Based on our data so far, we have shown that a tripartite complex comprising 
of NHE1, Akt and Hsp90 exist in in MEFPTEN-/- cells and not its wildtype 
counterpart. Utilizing different approaches to inhibit either Akt or Hsp90 
function, we have shown that the Akt–Hsp90 complex is imperative in the 
regulation of NHE1 protein stability in MEFPTEN-/- cells. This establishes a novel 
phenomenon that explains the increased stability of NHE1 protein acquired by 

















3.3 The NHE1-Hsp90-Akt complex is a model of breast cancer 
progression 
 
3.3.1 Regulation of NHE1 protein expression in MCF10AT1Kcl.2 series of 
breast cancer cell lines   
 
3.3.1.A Characterization of MCF10AT1Kcl.2 series of breast cancer cell lines   
 
In the present study, we have shown that Akt is imperative in the regulation of 
NHE1 protein expression in MEFPTEN-/- cells. Moreover, we have also 
established that the stability of NHE1 protein is largely influenced by binding to 
the Akt-Hsp90 complex at the membrane. Hence, to rule out the possibility 
that these findings were a peculiarity of a PTEN knockout mouse model 
(MEFPTEN-/-), we were keen in observing whether this hypothesis is 
physiologically relevant in a model of human breast cancer progression.    
 
The MCF10AT1Kcl.2 series of cell lines is an established cell culture model 
system derived from immortalized breast epithelial cells used for studying 
tumourigenesis occuring in breast cancer. This model encompasses a series 
of cell lines representing the various stages breast cancer progression. For 
our study, we utilized the benign MCF10A1 (10A1) which represents the 
immortalized mammary epithelial cell line (control), the pre-malignant 
MCF10AT1k (10AT1) generated by HRAS transformation of MCF10A1 and 
the malignant MCF10CA1a (CA1a) and MCF10CA1h (CA1h), which both 
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represent different carcinomas of tumor but derived from the same MCF10AT 
xenografts202. A schematic diagram representing the production and isolation 

























Figure 32: Isolation of MCF10AT1Kcl.2 series of breast epithelial cells. 
 
Flow chart representing the production and isolation of MCF10CA1 cell lines 
derived from MCF10A1normal breast epithelial cells. Rectangular boxes 
depicts cell cultures whereas ellipses represents solid tumours. The growth 
conditions the cell lines were cultured in is highlighted in red. (Adapted from 







Thus, before exploring our hypothesis, we first characterized the four cell lines 
by assessing the phosphorylation levels of Akt and NHE1 protein levels by 
western blot. Our data revealed that the phosphorylation of Akt at the Ser 473 
and Thr 308 sites was minimal in 10A1 control cells as compared to a slight 
increase in the pre-malignant cell line, 10AT1. On the contrary, Akt 
phosphorylation Ser 473 and Thr 308 sites was abundant in both the 
malignant cell lines, CA1a and CA1h in comparison to the non-tumourigenic 
cell line, 10A1 (Figure 33). In particular, Akt phosphorylation appeared to be 
the least at both Ser473 and Thr308 sites. This correlated with the lack of 
detectable total Akt, suggestive of rapid turnover of Akt in 10AT1. On the other 
hand, elevated levels of NHE1 were detected in the pre-malignant 10AT1 cell 
line in comparison with the non-tumorigenic 10A1 cells.  
 
Although CA1a and CA1h were derived from the same xenografts, these 
tumour cell lines adopt dissimilar differentiation patterns202. Similarly, it may 
not be surprising that CA1a appeared to express a higher level in NHE1 
protein expression as compared to CA1h which displayed the lowest levels of 
NHE1 across the MCF10AT1Kcl.2 series of cell lines (Figure 33). In addition, 
parallel with our findings in MEFPTEN-/- cell culture model, the 
hyperphosphorylation of Akt correlates with the increase in NHE1 protein 
expression detected in CA1a. Conversely, CA1h appeared to exhibit Akt 
hyperphosphorylation on both Ser473 and Th308 sites as compared to 10A1 
normal epithelial cell line. Also, contrary to CA1a, our data revealed that no 
correlation between Akt phosphorylation and NHE1 protein expression in 




              
Figure 33: Profiling of NHE1 expression and Akt phosphorylation in 
MCF10AT1Kcl.2 series of breast cancer cell lines  
 
MCF10A1, MCF10AT1, MCFCA1a, MCF10CA1h were grown in complete 
medium (5% horse serum, EGF, CTX, insulin, hydrocortisone) until 70% 
confluent. Total cell lysates were collected and assessed for NHE1 and Akt 
Serine 473 (p-Akt Ser 473), Threonine 308 (p-Akt Thr 308) phosphorylation 
and total Akt expression by western blot analysis. β-actin was used as loading 
control. Data shown is representative of two experiments.  
 
Hence, we next asked if the increase in protein expression observed in AT1 
and CA1a could be due to the increased half-life of the NHE1 protein. Thus, 
MCF10AT breast cancer cell lines were incubated with 100 μg/ml of 
cycloheximide to inhibit protein synthesis and the time-course study of 
intracellular NHE1 degradation was assessed by western blot. As a control, 
the c-Myc protein was used as a marker due to its short half-life of less than 
30 minutes177. To further analyse the western blot data, densitometric analysis 














normalized to β-actin and to its respective controls, is shown for all 
MCF10AT1Kcl.2 series of cell lines. 
 
As shown in Figure 34A, NHE1 expression was significantly diminished at the 
48hr timepoint in 10A1 control cells and cell death was observed at 72 hour 
timepoint. This suggests that the 10A1 non-tumourigenic cells inherit the least 
stable NHE1 in comparison to the rest of the MCF10AT series of breast 
epithelial cells (Figure 34A & 34B). Conversely, this observation was not 
apparent in pre-malignant 10AT1 cells, which displayed increased NHE1 
protein stability even up till 72 hours (Figure 34C). Quantitation analysis by 
densitometry indicates increased stability of mature NHE1 in 10AT1 cells 
(Figure 34D) was prolonged beyond 72 hours, in comparison to the rest of the 
MCF10AT series of breast epithelial cells. Conversely, densitometric analysis 
indicated that, in the presence of CHX, NHE1 appeared to be more stable in 
CA1a (~66-68 hours) in comparison to CA1h (~44 hours) (Figure 34F and 
34H). Taken together, these findings strongly suggest that the stability of 
NHE1 protein is most pronounced in the pre-malignant 10AT1 and is 
irrespective of the stage of tumour progression. Notably, the turnover of NHE1 
protein (~66-68 hours) appeared to be similar in CA1a and MEFPTEN-/- cells 
(Figure 3). A summary of approximate turnover of NHE1 across the 
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34I)   
Cell line Approximate half-life of NHE1 protein (represents 50% 
level of NHE1 protein remaining) 
MCF10A1 ~ less than 48 hrs 
 (cell death past 48hrs) 





Figure 34: NHE1 protein stability studies in cells in MCF10A1, 
MCF10AT1, MCF10CA1a and MCF10CA1h 
 
A) MCF10A1, (C) MCF10AT1, (E) MCF10CA1a (G) MCF10CA1h cells were 
treated with 100ug/ml cycloheximide and analysed by western blot at various 
timepoints between 0-72hrs. Densitometric analysis of band corresponding to 
mature NHE1 band in (B) MCF10A1, (D) MCF10AT1, (F) MCF10CA1a and 
(H) MCF10CA1h cells and normalized to β-actin and to its respective controls 
and are reported as percent remaining (horizontal line represents 50% level of 
NHE1 protein remaining). A representative blot from at least two independent 
experiments is shown for each protein. (I) Table summarizing the approximate 










3.3.2 Stabilisation of Akt induces formation of Hsp90/Akt/NHE1 complex 
in MCF10AT1   
 
3.3.2.A  Akt instability is predominant in pre-malignant MCF10AT1 cell line 
 
Since the detection of total Akt intensity appeared to be the lowest in 10AT1 in 
comparison to the rest of the MCF10AT1kcl.2 series of cell lines (Figure 34), 
we hypothesized that this may be the result of rapid turnover of Akt occurring 
in 10AT1 cells. As a measure to confirm this, we loaded varying amounts of 
total protein (10µg, 50 µg or 100 µg) from 10A1, 10AT1 and CA1a and 
subsequently examined the levels of Akt phosphorylation at Ser473 and 
Thr308 by western blot.  
 
In comparison with the 10A1 non-tumourigenic cells, the premalignant 10AT1 
displayed slightly increased Akt phosphorylation, followed by CA1a depicting 
the highest level of Akt phosphorylation at both Akt Ser 473 and Thr 308 sites 
(Figure 35). However, we reasoned that hyperphosphorylation of Akt 
detectable in CA1a cells compared to 10AT1, maybe a result of lesser amount 
of total Akt being able to be detected by western blot analysis in 10AT1. For 
instance, it is noteworthy to say that the level of Akt Ser 473 and Thr308 
phosphorylation detectable in 50µg of total protein from 10AT1 appears 
equivalent to Akt phosphorylation levels present in 10µg of total protein in 
CA1a. Hence, this indicates the possibility that 10AT1 cells may inherit a rapid 





Figure 35: Comparison of Akt phosphorylation levels in MCF10A series 
of breast cancer cell lines 
  
MCF10A1, MCF10AT1, MCFCA1a, were grown in 5% HS and total cell 
lysates were collected. 10µg, 50µg, 100µg of total protein for each cell line 
was assessed for Akt Serine 473 (p-Akt Ser 473), Threonine 308 (p-Akt Thr 







































3.3.2.B Inhibition of proteasome activity promotes detection of the NHE1-
Hsp90-Akt complex in MCF10AT1 cell line 
 
We previously showed that NHE1 stability is prolonged beyond 72 hours in 
10AT1 as compared to the rest of the MCF10AT1kcl.2 series of cell lines 
(Figure 34C & 34D). Hence, as a step further, we investigated if NHE1 stability 
was maintained through interaction with the Hsp90-Akt complex that was 
previously established in MEFPTEN-/- cells. To assess this, we 
immunoprecipitated NHE1 and control IgG in 10AT1 and 10A1 control cells 
and thereafter assessed by western blot. As expected, we found that physical 
association between NHE1 and Akt was undetectable by immunoblot analysis 
in 10A1 control cells (Figure 36A). Interestingly, NHE1-Akt binding was not 
detected in 10AT1 cells to be detectable by western blot (Figure 36B).  Thus, 
the lack of detectable NHE1-Akt complex in 10AT1 may be likely due to the 
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Figure 36: NHE-Akt complex is not detectable in MCF10AT1 and 
MCF10A1 control cells 
 
(A) MCF10A1 and (B) MCF10AT1 cells were grown in complete medium and 
lysates were immunoprecipitated with anti-NHE1 antibody or control IgG. The 
precipitates and inputs were analyzed by western blot using antibody against 
NHE1, Akt. A representative blot from at least two independent experiments is 
shown for each protein. 
 
 
On the other hand, we also validated both 10AT1 premalignant cells and 10A1 
control cells for the detection of Akt-Hsp90 complex by immunoprecipitating 
Akt or control IgG and assessing precipitated Hsp90 band by western blot. 





















Our data revealed that the Akt-Hsp90 complex was not detectable in both 
10A1 control cells (Figure 37A) and 10AT1 cells (Figure 37B). Taken together, 
our data confirms that NHE1 stability may not be dependent through 
interaction with Akt-Hsp90 complex in both 10AT1 premalignant cell line and 
10A1 control cells.  
 
Having proposed that Akt instability could account for the lack of NHE1-Akt 
binding in 10AT1 (Figure 37B), we next investigated if stabilizing Akt would 
promote the formation of NHE1-Akt binding. To demonstrate this, proteasome 
activity was inhibited using MG132 for 3 hours in 10AT1 cells prior to 
immunoprecipitation with anti-NHE1 or control IgG (Figure 38). The IgG 
control did not precipitate Hsp90, Akt or NHE1 band.  Surprisingly, our data 
showed that a substantial amount of total Akt and Hsp90 was 
immunoadsorbed by NHE1 antibody in MG132 treated in 10AT1 cell lysates 
as compared to untreated control. Although MG132 treatment did not induce 
increased expression of Akt or Hsp90, it is likely that MG132 mediated 
stabilization of Akt favoured the formation of Akt–Hsp90 complex that may 
possibly confer stability to NHE1. In addition, MG132 did not induce the 
expression of total Akt in the inputs. As mentioned earlier, we reason that it 
may be possible that the inhibition of proteasome may induce aggresome 
formation resulting in accumulation of Akt in perinuclear vesicles which may 
not be detectable in whole cell lysates but in insoluble fractions166. Taken 
together, these experiments provide strong evidence that the stability of total 










Figure 37: Akt-Hsp90 complex is not detectable in MCF10AT1 and 
MCF10A1  
 
(A) 10A1 and (B) 10AT1 cells were grown in complete medium and lysates 
were immunoprecipitated with anti-Akt antibody or control IgG. The 
precipitates and inputs were analysed by western blot using antibody against 
Akt and Hsp90. A representative blot from at least two independent 

































Figure 38: MG132-mediated inhibition induces NHE1-Hsp90-Akt complex 
in MCF10AT1 cell line 
 
MCF10AT1 cells were grown in complete medium for 24 hours and cell 
lysates were immunoprecipitated with anti-NHE1 antibody or control IgG. The 
precipitates and inputs were analyzed by western blot using antibody against 
NHE1, total Akt (T-Akt) and Hsp90. A representative blot from at least two 


































3.3.3 Akt regulates NHE1 protein expression in MCF10CA1a  
 
Within the series of MCF10AT1kcl.2 breast cancer cell lines, CA1a was 
selected as it inherits both hyperphosphorylation of Akt and increased 
expression of NHE1 protein. Hence, similar to the MEFPTEN-/- cell model, we 
investigated whether Akt had an effect on NHE1 expression. PI3-K/Akt 
pathway was inhibited using various concentrations of LY294002 treatment 
(25µM or 50µM) for 3 hours in CA1a cells. Afterwhich, cell lysates were 
collected and assessed by immunoblot analysis. 
 
Blockade of PI3-K pathway mediated by LY294002 diminished Akt 
phosphorylation significantly at both different concentrations of LY294002 with 
a more significant effect observed in 50µM concentration of LY294002 (Figure 
39). Moreover, a sharp decline in NHE1 protein expression was observed 
upon LY294002 treatment in CA1a cells. Thus, LY294002-induced decrease 
in PIP3 levels and preventing the membrane recruitment of Akt downregulated 





Figure 39: Effect of LY294002 on NHE1 protein expression in 
MCF10CA1a 
 
MCF10CA1a cells were treated with various doses of LY294002 (25 or 50µM) 
or (DMSO as a control) for 3 hours. Total cell lysates were subjected to 
western blot analysis to detect NHE1and total Akt. The efficacy of LY294002 
was determined through the detection of phosphorylated Akt (p-Akt Ser 473). 
β-Actin was used as loading control. A representative blot from at least two 
independent experiments is shown for each protein. 
  
 
Another way to assess the effect of Akt on NHE1 is to inhibit Akt using specific 
siRNA. Prior to this, we first assessed whole cell lysates by western blot to 
determine the Akt isoforms that are present in CA1a cells. Our data showed 
that Akt 1 and 2 isoforms were present but the levels of isoform 3 was too low 
to be detected by immunoblot analysis (Figure 40). Interestingly, down-
regulation by specific siRNA against Akt isoforms 1 & 2 also resulted in the 
diminished expression of the NHE1 protein expression in CA1a breast cancer 
cells (Figure 41). Furthermore, this finding was consistent with similar 




data suggests the Akt may be involved in the regulation of NHE1 protein 
expression in CA1a breast cancer cells.  
 
Figure 40: Akt 1 and 2 are detectable in MCF10CA1a  
 
MCFCA1a cells were grown in complete medium and total cell lysates were 
collected and analyzed by western blot on the same gel to detect (A) Akt 
isoforms 1, 2 and 3. β-actin was used as a loading control.  
 
  
         
Figure 41: Silencing Akt induces downregulation of NHE1 protein 
expression in MCF10CA1a 
 
MCF10CA1a cells were transfected with control siRNA (siCo) or Akt siRNA 
(siAkt). Cell lysates were subjected to western blot analysis to detect NHE1, 
Hsp90 and total Akt. β-actin was used as loading control. A representative blot 










3.3.4 NHE1 interacts with Akt in MCF10CA1a and not MCF10CA1h 
 
We have previously established that hyperphosphorylated Akt was detected in 
both CA1a and CA1h which were derived from the same xenograft source 
(Figure 33). Also, NHE1 protein appeared to be more stable in CA1a and 
CA1h (Figure 34F and 34H) than its wildtype counterpart, 10A1 (Figure 34B). 
However, in comparison with the rest of the MCF10AT1kcl.2 series of breast 
cancer cell lines, the malignant CA1h displayed the lowest NHE1 expression 
levels (Figure 33). Hence, we were keen to know if Akt forms a complex with 
NHE1 in CA1a and CA1h as observed in MEFPTEN-/- cells. 
 
To verify this interaction, co-immunoprecipitation analysis was performed in 
CA1a and CA1h lysates using anti-NHE1 and assessed by western blot. 
Interestingly, immunoprecipitation with anti-NHE1 antibody readily detected 
Akt by western blot in CA1a cells (Figure 42A). On the contrary, CA1h showed 
no interaction was detectable between NHE1 and Akt (Figure 42B). Hence, it 
is likely that Akt may play a role in regulating NHE1 in CA1a cells, similar to 
MEFPTEN-/- cells. Although Akt appears hyperphosphorylated in CA1h cells, no 














Figure 42: NHE1-Akt interaction is detectable in MCF10CA1a and not in 
MCF10CA1h cells 
 
Lysates from (A) MCF10CA1a and (B) MCF10CA1h cells were 
immunoprecipitated with anti-NHE1 antibody or anti-IgG antibody and 
analyzed by western blot using antibody against NHE1, Akt. A representative 




















3.3.5 Akt-Hsp90 complex is detectable in MCF10CA1a but is absent in 
MCF10CA1h breast cancer cells 
 
Hsp90 has been shown to bind to Akt and prevent its proteosomal mediated 
degradation167. Hence, we were curious to know as to whether Hsp90 is 
involved in stabilizing Akt since hyperphosphorylation of Akt was detected in 
CA1a and CA1h cells. To examine this possibility, CA1a and CA1h lysates 
were immunoprecipitated with Akt or control IgG. This was followed by 
western blot analysis to detect Hsp90-Akt complex formation in both fractions. 
 
The immunoblot analysis showed that no band was detectable corresponding 
to IgG band (Figure 43A & 43B).  Interestingly, our results show that Hsp90-
Akt complex present in CA1a cells but is undetectable in CA1h cells. This data 
confirms that Hsp90 is crucial in maintaining the hyperphosphorylation of Akt 
in CA1a. Conversely, Akt stability may not be dependent on Hsp90 in CA1h 
cells. Indeed, this proposes a possibility that the Akt-Hsp90 complex may be 
involved in enhancing the stability of NHE1 protein at the plasma membrane 















Figure 43: Akt-Hsp90 complex is detected in MCF10CA1a but not 
MCF10CA1h breast epithelial cells 
 
Lysates from (A) MCF10CA1a and (B) MCF10CA1h cells were 
immunoprecipitated with anti-Akt antibody or anti-IgG antibody and analyzed 
by western blot using antibody against NHE1, Akt. A representative blot from 

































3.3.6 Hsp90 stabilizes NHE1 protein expression through direct 
interaction in MCF10Ca1a breast cancer cell lines  
 
3.3.6.A  NHE1 interacts with Hsp90 at the plasma membrane in MCF10CA1a 
breast cancer cells 
 
Based on our data so far, we have proposed that Hsp90 plays a crucial role in 
the prolonged stability of NHE1 protein observed in MEFPTEN-/- cells as 
compared to its wildtype counterpart. Moreover, we showed that this is 
mediated through the physical interaction between Hsp90 and NHE1. Thus, 
we questioned if the molecular chaperone, Hsp90 may be involved in 
preventing NHE1 degradation in CA1a breast cancer cells.  
 
To address this question, we first determined the localization of Hsp90 by 
subjecting CA1a cells through membrane-cytosol fractionation (Figure 44A). In 
line with prior observations in MEFPTEN-/- cells (Figure 5), not only was Hsp90 
protein detected in the cytosol but also at the plasma membrane in CA1a. In 
addition, Hsp90 expression level appeared to be enhanced in the cytosol 
fraction as compared to the membrane fraction. As a step further to confirm 
the association of NHE1 and Hsp90, pull-down assay using anti-NHE1 or 
control IgG antibody in CA1a cells was performed (Figure 45). Our 
observations verified the direct interaction between NHE1 and Hsp90, strongly 
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suggesting that Hsp90 may be involved in the stability of NHE1 protein in 
CA1a cell line (Figure 45).  




Figure 44: Hsp90 is present at the membrane in MCF10CA1a breast 
cancer cells 
  
(A) MCF10CA1a cells were grown in complete medium for 24 hrs. Cell lysates 
were then subjected to membrane-cytosol fractionation and analyzed by 
western blot to detect NHE1, Hsp90 and β-actin was used as a loading 
control. (B) Lysates in (A) were assessed on a separate gel by western blot to 
detect VDAC (membrane) and Cu/Zn SOD (cytosolic) control. A 

























Figure 45: NHE1 interacts with HSP90 in MCF10CA1a cells 
 
Lysates from MCF10CA1a cells were immunoprecipitated with anti-NHE1 
antibody or control IgG. Immunoprecipitates (IP) and inputs were analyzed by 
western blot using antibody against NHE1, Hsp90. ** corresponds to a non-
specific band that appeared due to stripping and reprobing the blot used for 
detection of Hsp90.  A representative blot from at least two independent 



























3.3.6.B Hsp90-Akt complex prevents degradation of NHE1 protein in 
MCF10CA1a 
 
In the presence of a protein synthesis inhibitor, CHX, the degradation of NHE1 
was drastically delayed in CA1a cells as compared to 10A1 control cells 
(Figure 34A & 34E). We next hypothesized that Hsp90 may play a role in the 
stabilization of NHE1 protein in CA1a breast cancer cell line. As a step 
towards proving this hypothesis, we transfected CA1a cells with specific 
siRNA against Hsp90 or negative control for 72 hours, afterwhich cell lysates 
were examined by immunoblot analysis (Figure 46). Marked reduction of 
Hsp90 expression upon silencing was accompanied by a sharp decrease in 
NHE1 protein levels (Figure 46). Here, we provide evidence that suggests that 
the abrogation of Hsp90 function destabilizes NHE1 protein levels in CA1a 
cells, as detected in MEFPTEN-/- cells (Figure 8).  
 
Based on our data, this further proposes that Akt-Hsp90 complex may be 
involved in stabilizing NHE1 in CA1a. Hence, this finding picqued our interest 
as it led us to question if Akt, Hsp90 and NHE1 may exist as a stable complex 
at the membrane in CA1a breast cancer cells. To answer this, the ability of 
NHE1 to associate with Akt or Hsp90 in CA1a cells were assayed by 
immunoprecipitation followed by immunoblot analysis (Figure 47). As a 
control, normal rabbit IgG did not precipitate Akt or Hsp90 or NHE1.  Here, we 
show that NHE1 forms a tripartite complex with Hsp90 and Akt in MCF10 
CA1a breast cancer cell line which is in accordance with our findings in 
MEFPTEN-/- cells (Figure 27 & 28). Taken together, these experiments suggest 
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that Hsp90 confers increased stability to NHE1 in CA1a breast cancer cells by 
protecting it from degradation and this may be mediated by the physical 
























                 
Figure 46: Silencing Hsp90 causes downregulation of NHE1 protein 
expression in MCF10CA1a 
 
(A) MCF10CA1a cells were transfected with control siRNA (siCo) or Hsp90 
siRNA (siHsp90) and harvested 72 hours post transfection. Lysates were 
subjected to western blot analysis to detect for NHE1, Hsp90, total Akt and β-
actin was used as loading control. A representative blot from at least two 





Figure 47: NHE1 interacts with Akt and HSP90 in MCF10CA1a cells 
 
Lysates from MCF10CA1a cells were immunoprecipitated with anti-NHE1 
antibody  and analyzed by western blot using antibody against NHE1, Akt and 
Hsp90. ** corresponds to a non-specific band that appeared due to stripping 
and reprobing the blot used for detection of Hsp90. A representative blot from 
at least two independent experiments is shown for each protein. 
















3.4 NHE1 regulates Akt phosphorylation at Ser 473 site in MEFPTEN-/- and 
MCF10CA1a cells 
 
3.4.1 Downregulation of NHE1 dephosphorylates Akt at Ser 473 in 
MEFPTEN-/- and MCF10CA1a cells 
 
The mTORC2 complex is responsible for the direct phosphorylation of Akt at 
the Ser473 site91,204. This would require the mTORC2 complex to colocalize 
with Akt at the plasma membrane205. Indeed, we have shown that the 
hyperphosphorylation of Akt exists in both MEFPTEN-/- and CA1a cells. 
Interestingly, our data demonstrates that silencing NHE1 in MEFPTEN-/- cells 
induces the dephosphorylation of Akt at Ser 473 site, whereas the expression 
of total Akt remains unaffected (Appendix A). Hence, this data implies a 
correlation between NHE1 and the activation of Akt. On the other hand, our 
results also indicate that knockdown of Hsp90 not only downregulates NHE1 
protein expression but also decreases Akt phosphorylation at the Ser 473 site 
but not total Akt expression, in both MEFPTEN-/- cells and CA1a cells (Figure 














Figure 48: Silencing Hsp90 causes downregulation of NHE1 protein 
expression in both MEFPTEN+/+ and MEFPTEN-/- cells 
 
(A) MEFPTEN-/- and (B) MCF10CA1a cells were transfected with 150nM control 
siRNA (siControl) or 150nM Hsp90 siRNA (siHsp90) for 72hr. Cell lysates 
were subjected to western blot analysis to detect for NHE1, Hsp90 and β-actin 
was used as loading control. ** corresponds to a non-specific band that 
appeared due to stripping and reprobing the blot used for detection of Hsp90. 




















Taken together, our findings suggest that the activation of Akt may have an 
effect on NHE1 expression in both MEFPTEN-/- cells and CA1a cells. Hence, we 
hypothesized that mTORC2 which phosphorylates Akt on the Ser 473 site, 
may possibly have a direct effect on the expression of NHE1 protein in both 
MEFPTEN-/- cells and CA1a cells. Thus, this prompted us to examine the role of 
mTOR and Rictor of the mTORC2 complex in the regulation of NHE1 protein 
expression in MEFPTEN-/- cells and CA1a breast epithelial cells. 
 
 
To evaluate this, we first prepared membrane–cytosol fractions of both cell 
lines and examined expression of the target proteins by immunoblot (Figure 
49A & 50A). Previous studies have reported the detection of Rictor enriched in 
plasma membranes of PTEN-null prostate epithelial cells91. In parallel with 
these findings, we show that both mTOR and Rictor are present at the plasma 



















Figure 49: mTOR/Rictor is detected at the plasma membrane in MEFPTEN-/- 
cells 
 
(A) MEFPTEN-/- cells were grown in 10%/FBS until 70% confluent. Cell lysates 
were then subjected to membrane-cytosol fractionation and analyzed by 
western blot to detect mTOR, Rictor and β-actin was used as a loading 
control. (B) Lysates in (A) were assessed on a separate gel by western blot to 
detect VDAC (membrane) and Cu/Zn SOD (cytosolic) control. A 
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Figure 50: mTOR/Rictor is detected at the plasma membrane in 
MCF10Ca1a cells 
 
(A) MCF10CA1a cells were grown in complete medium for 24 hrs. Cell lysates 
were then subjected to membrane-cytosol fractionation and analyzed by 
western blot to detect mTOR, Rictor and β-actin was used as a loading 
control. (B) Lysates in (A) were assessed on a separate gel by western blot to 
detect VDAC (membrane) and Cu/Zn SOD (cytosolic) control. A 


























In an effort to further investigate the role of mTORC2 complex in the 
regulation of NHE1, we then immunoprecipitated NHE1 in in both MEFPTEN-/- 
cells and CA1a cells and assessed both the inputs and immunoprecipitates by 
western blot analysis. Control IgG showed no detectable band corresponding 
to mTOR or Rictor. Surprisingly, NHE1 pulldowns showed a clearly detectable 
band corresponding to mTOR and Rictor in MEFPTEN-/- cells (Figure 51A). 
These findings were also in consistent in CA1a breast cancer cells (Figure 
51B). Together, these experiments strongly suggest that mTORC2 complex 
physically interacts with NHE1 protein and regulates the Akt phosphorylation 
at the Ser 473 site. Also, it may be likely that the mTORC2 complex bound 
NHE1 complex may also add to the hyperphosphorylation status of Akt 




















                                              
Figure 51: NHE1 interacts with mTOR/Rictor complex at the membrane in 
MEFPTEN-/- cells and MCF10CA1a cells 
 
MEFPTEN-/- cells and MCF10CA1a cells were grown for 24 hours and cell 
lysates were immunoprecipitated with anti-NHE1 antibody.  The precipitates 
and lysates were analyzed by western blot using antibody against mTOR and 
Rictor. A representative blot from at least two independent experiments is 


























CHAPTER 4: DISCUSSION 
 
4.1 NHE1 is a potential client protein of Hsp90 in MEFPTEN-/- cells 
 
4.1.1 Increased stability of NHE1 protein in MEFPTEN-/- cells in comparison 
to MEFPTEN+/+ cells 
 
The regulatory mechanisms that control the protein abundance and post-
translational modifications of proteins within a cell are complex. In most cases, 
the level of mRNA transcripts of the target gene is often correlated with its 
protein expression. Our group has previously shown that a slight increase in 
intracellular superoxide induces NHE1 gene promoter activity which translates 
to increased NHE1 protein expression, promoting cell survival through 
resistance against death stimuli34. Similar observations were made by Rao et 
al.206, as they highlighted that prior to differentiation into granulocyte-like cells, 
an increase in NHE1 activity is subsequently followed by a strong correlation 
between the elevation in mRNA levels and protein levels of NHE1. Therefore, 
it is plausible that NHE1 protein expression may be tightly associated with its 
gene transcription. In contrast to this notion, the lack of correlation between 
mRNA and protein levels has been observed in certain tumour cell lines. For 
instance, a microarray study performed by Chen et al.207, whereby some 
genes expressed in lung adenocarcinoma depicted negative correlation 
between mRNA and protein levels. Similarly non-coordinated mRNA and 
protein levels were also observed for metalloproteinases such as MMP-2 and 
MMP-9 in prostate cancer cells208. 
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In this study, the discordance in NHE1 mRNA and protein levels suggests that 
an increase in transcription was not a factor that led to elevated levels of 
NHE1 protein in MEFPTEN-/- cells. This also highlights a possibility that NHE1 
mRNA and protein expression levels may not necessarily have a causal link. It 
is likely that NHE1 protein expression may be differentially regulated in 
MEFPTEN-/- cells.  
 
The turnover of endogenous plasmalemmal NHE1 in epithelial cells (CaCo-2 
or A6) and fibroblasts (PS120) have considerably longer half-lives (20-24hr) 
as compared to other isoforms NHE2 (14hr) or NHE3 (3hr)209,210. In our 
current study, through the inhibition of de novo protein synthesis using 
Cycloheximide (CHX), we found that NHE1 exhibits a prolonged half-life in 
MEFPTEN-/- cells as compared to MEFPTEN+/+ cells. This suggests a possibility 
that other factors may be involved in increasing the stability of NHE1 in 
MEFPTEN-/- cells. These findings are in agreement with a study by Agoston et 
al.211, whereby an increase in DNA methyltransferase 1 (DNMT1) protein 
stability was detected in MCF-7 breast cancer cells as compared non-
tumourigenic breast epithelial cells. In addition, they also demonstrated that 
the increased half-life of DNMT1 was not due to increased mRNA levels211.  
 
The modulation of protein stability may confer an added advantage to a 
protein in a tumourigenic environment. For instance, Myc, an oncogenic 
transcription factor has been shown to regulate genes involved in cell 
metabolism, growth, and progression in cancer212,213. Interestingly, a recent 
study reported that I kappa B kinase (IKK), a mediator of inflammatory 
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responses, regulates Myc expression by enhancing its protein stability and 
increase the invasive capability of MCF7 breast cancer cells214. Another effect 
of increase in protein stability was observed by Byles et al.215, whereby 
PI3K/IGF-1R signalling enhanced the protein stability of SIRT1, a NAD-
dependent histone/protein deacetylase which is predominantly a nuclear 
protein. Moreover, the increase in protein stability also led to the aberrant 
cytoplasmic localization of SIRT1 in malignantly transformed cells and cancer 
cell lines. Thus, it is possible that enhanced protein stability may offer an 
added advantage particularly in a tumourigenic environment. On that note, our 
study showed that MG132-mediated proteasome inhibition did not show any 
appreciable increase in NHE1 levels in MEFPTEN-/- cells as compared to 
MEFPTEN+/+ cells.  Hence, we postulated that a delay in degradation may be 
increasing NHE1 protein stability in MEFPTEN-/- cells.  
 
The current literature suggests that CHP group of proteins may act as 
important cofactors in the regulation of NHE136. Recent studies identified that 
the Calcineurin B homologous protein 1 (CHP1) prevents degradation of 
NHE1 by masking a disposal signal in CV1 monkey cell line43. Moreover, they 
demonstrated that deletion of the CHP1 binding site on NHE1 led to shorter 
half-lives in comparison to wild-type NHE1 with retained the CHP1 binding 
site. Hence, it is thought to be crucial for the stability and proper localization of 
NHE1 to the plasma membrane43,216. Similarly, Zaun et al.217, proposed that 
Calcineurin B homologous protein 3 (CHP3) is involved in the maturation and 
cell surface stability of NHE1 in Chinese hamster ovary AP-1 cells. However, it 
is noteworthy that studies supporting the role of CHP1 or CHP3 in the 
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regulation of NHE1 stability were mainly established in a non-tumorigenic 
environment. It may also be likely that the role of CHP1 or CHP3 on NHE1 
stability could be directed towards a phenomenon that exists in normal cells. 
Conversely, the Calcineurin B homologous protein 2 (CHP2), has been shown 
to be highly abundant in tumour cells218,219. However, it was proposed that in 
malignantly transformed cells, NHE1-CHP2 complex functions to maintain a 
high pHi and to protect from serum depletion-induced cell death
218,219. 
However, the exact mechanism by which CHP2 activates NHE1 and the role 
of CHP2 on NHE1 stability still remains elusive. Thus, in the current study, it is 
likely that other helper proteins may be involved in increasing the stability of 
NHE1 in MEFPTEN-/- cells. 
 
Molecular chaperones are helper proteins that have been shown to regulate 
proper protein folding and quality control of proteins220. Indeed, Hsp90 is a 
well characterized chaperone protein that plays a key role in stabilizing and 
promoting functional maturation of certain signalling proteins involved in cell 
growth and survival165. One example would be the Ser/Thr LIMK1 kinase that 
is thought to regulate cytoskeletal dynamics through the inactivating 
phosphorylation of cofilin221. Interestingly, a report by Li et al.222, demonstrated 
Hsp90’s role in the regulation of LIMK1 stability. Their study shows that the 
protein level of LIMK1 was drastically increased in invasive breast cancer cell 
lines in comparison to non-tumourigenic and normal cells. Moreover, the 
enhanced stability of LIMK1 was not due to an increase in transcription but 
through the association of Hsp90217. Additionally, another study established 
that Hsp90 is involved in prolonging the stability of the epidermal growth factor 
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(EGFR) which is involved in promoting epithelial cancers223. Thus, this led us 
to investigate as to whether molecular chaperones may be responsible in 
regulating the stability of NHE1 in MEFPTEN-/- cells.  
 
Upon surveying the literature, we found that Heat shock protein 70 (Hsp70) 
was the only known molecular chaperone reported to play a role in the 
biosynthesis of NHE1224. Nevertheless the regulatory mechanisms were not 
thoroughly investigated. Interestingly, in our study, we showed that enhanced 
binding between Hsp90 and NHE1 exists in MEFPTEN-/- cells.  
 
4.1.2 Hsp90 confers protection to NHE1 in MEFPTEN-/- cells 
 
Although chaperones have been shown to regulate numerous cellular 
proteins220, little evidence has been reported on their part in the regulation of 
ion exchanger proteins. Many groups have identified Hsp90 as a key facilitator 
of tumour cell survival as its chaperone machinery is able to protect a vast 
number of mutated or overexpressed proteins from being targeted for 
degradation and to prevent misfolding or aggregation162,165.  
 
Zhou et al.225, have shown that inhibition of Hsp90 using Geldanamycin (GM), 
promotes the degradation of its client protein, ErbB2, member of the ErbB 
receptor tyrosine kinase family. This occurs through the destabilization of the 
Hsp90/ErbB2 complex and subjecting ErbB2 to be degraded via the 
proteasome involving the E3 ligase, C-terminus of Hsc70-interacting protein 
(CHIP). Similar observations were made by Whitesell and colleagues226, 
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whereby, another well-known Hsp90 client protein, glucocorticoid receptor 
(GR) is subjected to proteosomal mediated degradation in the presence of 
GM.  In agreement with these reports, our project demonstrated that 
abrogation of Hsp90 function using pharmacological or molecular inhibition 
had a significant effect on NHE1 protein levels particularly in MEFPTEN-/- cells. 
Thus, our findings support that NHE1 may be protected from degradation 
through binding with Hsp90 in MEFPTEN-/- cells. 
 
In general, the absence of Hsp90 may lead to the drastic reduction in the half-
life of its client proteins. Accordingly, Ahsan and colleagues223, showed that 
both inhibition of Hsp90 and new protein synthesis using Cycloheximide 
(CHX) dramatically decreased the half-life of EGFR as compared to control 
cells, indicative of Hsp90’s role in the stability of its client protein, EGFR. 
Similar observations were made Li et al.227, demonstrating that abrogation of 
Hsp90 function destablizes its client protein, MDM2. In the current study, we       
showed that the stability of NHE1 was highly dependent on Hsp90 in  
MEFPTEN-/- cells. Thus, our observation purports the view that NHE1 may be 
another potential substrate of Hsp90 chaperone. Moreover, our data proposes 
a new rationale that NHE1 may require the chaperoning activity of Hsp90 for 
its stability in MEFPTEN-/- cells.   
 
In general, cellular proteins are subjected to modification through the covalent 
addition of ubiquitin in order to regulate various biological processes such as 
protein turnover, protein-protein interactions and subcellular targeting228,229. 
Polyubiquitination, particularly involving addition of ubiquitin molecules at the  
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lysine-48 residue, subjects the target protein to degradation through 
proteasome machinery230. Although in some cases, proteasome may not 
necessarily require ubiquitination as a pre-requisite, most degradation 
executed by proteasome machinery appears to be ubiquitin-dependent231.   
 
Although most studies have highlighted the importance of Hsp90 in 
maintaining the integrity of its client proteins, little is known on its role in 
preventing the ubiquitination of its client proteins. In line with this notion, Kim 
et al232 have demonstrated that apart from preventing the proteasome-
mediated degradation of 40S ribosomal proteins such as rpS3 and rpS6, 
Hsp90 prevents the ubiquitination of both ribosomal proteins. Therefore, it is 
conceivable that Hsp90 may be involved in preventing the ubiquitination of 
NHE1 to a slight extent and this precedes proteasome-mediated degradation 
of NHE1 in MEFPTEN-/- cell lines. Notably, P4D1 detects both ubiquitin 
monomers and polyubiquitination. Therefore, apart from polyubiquitinated 
NHE1 being targeted by proteasome, a small pool of intracellular NHE1 may 
be mono-ubiquitinated as well, however further investigations are needed to 
confirm this phenomenon.  
 
Hsp90 has been shown to play an imperative role in cell survival by mediating 
the stabilization of various cellular proteins. Indeed, previous studies have 
identified some of Hsp90 client proteins such as Akt166 and inhibitor of κB (IκB) 
kinase (IKK) complex233, to be prosurvival and anti-apoptotic. Additionally, the 
ansamycin antibiotic, Geldanamycin has been shown to exhibit anti-
proliferative effects in various of tumor cell lines by blocking the function of 
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Hsp90234,235. Interestingly, in recent years, studies have also highlighted the 
role of NHE1 in tumour cell survival74,193,236. Futhermore, previous studies 
have also demonstrated that upregulation of Hsp90 expression is predominant 
in tumor cells than in normal cells by 2 to 10 folds237-239. In the current 
investigation, the cytoprotective role of Hsp90 on NHE1 was demonstrated as 
GM-treated MEFPTEN-/- cells displayed enhanced sensitivity to cell death in 
comparison to wild-type cells. Together, our data suggests Hsp90 mediated 
stability of NHE1 may be significant for its role in cell survival. However, 
further investigation using cell viability assays may be required to assess the 
effect of Hsp90 on the stability of NHE1 in cell survival. Hence, our study 
proposes that Hsp90 confers protection to NHE1 via two possible 
mechanisms. Firstly, Hsp90 binding to NHE1 may physically blocks access of 
E3 ligases that may ubiquitinate NHE1. This is supported by the fact that an 
increase in ubiquitinated NHE1 species was observed in the presence of 
Geldanamycin. Secondly, Hsp90 binding prevents the uptake of ubiquitinated 
NHE1 by proteasome machinery. This observation is in parallel with 
increasing number of studies that show that in the presence of GM, Hsp90 
client proteins such as p53, Raf-1 and cystic fibrosis transmembrane 
conductance regulator are prone to proteasome- mediated degradation240-243. 
This suggests a possibility that NHE1 may be a potential substrate of Hsp90.   
The chaperone Hsp90 performs its function with the help of a complex 
comprising of co-chaperones such as cdc37, p60Hop, and Hsp70244. Thus, 
further experiments involving anti-NHE1 pull down of Hsp90 and its specific 
co-chaperones such as Cdc37, in GM-treated MEFPTEN-/- cells, may provide 
more insight towards the possibility of NHE1 being a client protein of Hsp90. 
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4.2 Akt mediates regulation of NHE1 in MEFPTEN-/- cells  
 
4.2.1 Regulation of NHE1 by Akt occurs at a protein level and not 
transcriptionally in MEFPTEN-/- cells  
 
The transmembrane segment of NHE1 spanning across the plasma 
membrane regulates pHi through Na+ and H+ exchange245. In contrast, the 
cytoplasmic C-terminal tail acts as a scaffold for many interacting proteins 
involved in various cell signalling pathways52. Growing evidence suggests a 
strong link between NHE1 and PI3K/Akt pathway in promoting cell survival. 
For instance, Wu et al.74, have shown that complex formation of NHE1-ERM 
(Ezrin/Radixin/Moesin) promotes cell survival in renal tubular epithelial cells74. 
Since ERM has been previously to shown to interact with PI3K58, specific PI3K 
inhibitors or mutants that disrupt ERM-PI3K interaction further enhanced 
staurosporine-induced apoptosis in renal tubular epithelial cells74. Thus, cell 
survival was shown to occur in a sequential manner whereby NHE1-ERM 
complex was followed by the recruitment of PI3K and subsequent activation of 
Akt mediated cell survival. 
 
In another study, Jawdeh et al.75, demonstrated the role of NHE1 in cell 
survival through its interaction with phosphoinositides. Their work showed that 
low affinity binding exists between NHE1 and PIP2 or PIP3 in kidney proximal 
tubule cells. However, in the presence of apoptotic triggers or cytosolic 
acidification, enhanced interaction between PIP2 and NHE1 and subsequent 
PI3K activation and PIP2 phosphorylation occurs. The resulting PIP3 then 
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dually mediates Akt-mediated survival signalling and blunts NHE1 activity 
through competitive inhibition with reduced levels of PIP2 for binding to 
NHE175. Hence, to date, although NHE1 has been shown to be involved in 
PI3K/Akt pathway-mediated cell survival, no evidence has been presented 
which pinpoints towards NHE1 and Akt working directly to regulate cellular 
survival.   
 
In our study, our observations point towards a strong correlation between 
NHE1 protein expression and Akt in MEFPTEN-/- cells. Firstly, By utilizing two 
structurally dissimilar inhibitors, LY294002 (25μM) and Wortmannin (50nM) 
and diminishing the available PIP3 levels, our data suggest that the prevention 
of Akt membrane recruitment downregulated NHE1 protein expression in 
MEFPTEN-/- cells. Secondly, this notion was further supported as knockdown of 
Akt using specific siRNA was concomitant with the decrease of NHE1 protein 
levels. Thirdly, the small molecule inhibitor, API-1 which prevents the 
translocation of Akt by binding to the PH domain of Akt191 blunted NHE1 levels 
drastically. Taken together, we demonstrated that rather than its activity, the 
membrane recruitment of Akt is imperative and has a direct effect on NHE1 
protein expression. Thus, our results are in agreement with the fact that NHE1 
protein may be functionally dependent on Akt in MEFPTEN-/- cell model.  
 
In the current literature, one of the proteins that have been shown to be 
regulated by Akt is the enzyme, cyclooxygenase-2 (COX2) which plays a role 
in the synthesis of prostaglandins246. Indeed, previous reports indicate that Akt 
mediated regulation of COX2 occurs at both the transcriptional and protein 
 161 
 
levels in human endometrial cancer cells that incur mutated–PTEN247. 
However, in our investigation, we found that both knockdown of Akt and 
LY294002 affected only the NHE1 protein levels and showed unappreciable 
changes in NHE1 mRNA expression. Together, these findings purports the 
fact that Akt mediated regulation of NHE1 occurs at the protein rather than at 




















4.2.2 Regulation of NHE1 by Akt in MEFPTEN-/- cells is independent of 
NHE1 activity  
 
Akt-mediated cell survival in renal tubular epithelial cells was thought to 
involve both the upregulation of NHE1 activity and NHE1-ERM binding 
concurrently74. Moreover, a recent study reported that the elevation of NHE1 
activity and NHE1 translocation to the leading edge in migrating fibroblasts 
occurs in an Akt-dependent manner during PDGF-AA-induced cell 
migration248. Furthermore, studies by Wu et al.74, have established that both 
NHE1 activity and scaffolding function occurs concurrently to mediate PI3K 
dependent cell survival in renal tubular epithelial cells.  Hence, these reports 
purport the fact that NHE1 activity may be crucial in supporting its scaffolding 
or other cellular functions that involve Akt-dependent pathways. In contrast to 
these reports, we have shown that association of NHE1 and Akt is 
independent of the activity of NHE1 in MEFPTEN-/- cells (Appendix A). We 
demonstrated this through EIPA or Cariporide-mediated inhibition of NHE1 
activity. The use of EIPA or Cariporide did not cause any appreciable change 
in NHE1 expression or Akt phosphorylated levels in MEFPTEN-/- cells   
(Appendix A). These findings are similar to a study that showed NHE1-ERM 
mediated regulation of cytoskeletal organization and cell shape is independent 
of ion translocation, even in unstimulated cells58. Taken together, we could 
justify that both increase in NHE1 expression and exchanger activity may not 
necessarily work in parallel to regulate cellular functions in all cell types. Thus, 
in our study, it is likely that the Akt-mediated regulation of NHE1 protein is 
independent of NHE1 activity in MEFPTEN-/- cells. 
 163 
 
4.2.3 NHE1 acts as a scaffold for Akt 
 
NHE1 plays a pivotal role in the tight regulation of pH and cell volume51,249. 
Apart from its role in ion homeostasis, NHE1 has been shown to act as a 
scaffold and modulate the activity of interacting proteins involved in various 
signalling pathways that are imperative in biological functions such as cell 
survival, proliferation and differentiation (reviewed in250). However, one 
unresolved question arising from these findings is whether the mechanism by 
which Akt influences the NHE1 expression occurs in a direct or indirect 
manner. Indeed, NHE1 has been identified as a bona fide Akt substrate 
through a Ser648 phosphorylation that upregulates NHE1 activity and induces 
regulated disassembly of actin stress fibers and cell proliferation in 
fibroblasts76. However, it is notable that these studies were performed in vitro. 
In contrast, Akt mediated phosphorylation at the Ser648 site blunted NHE1 
activity in cardiac myocytes. However, both studies lacked evidence on the 
physical interaction between NHE1 and Akt.  
 
In the current study, we revealed that NHE1 and Akt directly bind to each 
other to form a strong complex in MEFPTEN-/- cells in contrast to a weak NHE1-
Akt complex was observed in MEFPTEN+/+ cells. We reasoned that this 
interaction maybe more of a transient reaction and exist at a basal level as 
compared to that discovered in MEFPTEN-/- cells. Hence, we postulated Akt and 
NHE1 could be present in the same signalling platform on the membrane or at 
least in close proximity of each other in the signalling platform. It is plausible 
that NHE1 could act as a scaffold for Akt-mediated signalling. Moreover, the 
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close proximity through this interaction facilitates Akt to regulate NHE1 protein 
expression and amplify the signals of PI3K pathway in the absence of PTEN. 
 
4.2.4 Hsp90 protects hyperphosphorylated Akt from degradation in 
MEFPTEN-/- cells 
 
In normal cells, a fully active Akt kinase that dissociates from the plasma 
membrane is rapidly targeted for dephosphorylation carried out by PP2A and 
PHLPP, at both the Thr 308 and Ser 473 sites, respectively. Furthermore, it 
has been suggested that Akt phosphorylation at the Ser 473 site induces a 
Lys-48-linked polyubiquitination of Akt, which consequently leads to Akt being 
targeted for proteasomal degradation195. However, in the current study, we 
observed that the suppression of activation of Akt using PI3K inhibitors 
LY294002or Wortmannin, delayed the dephosphorylation of Akt in MEFPTEN-/- 
cells as compared to wildtype cells. This observation further supported the fact 
that Akt hyperphosphorylation exist in in MEFPTEN-/- cells. Therefore, in our 
study, we hypothesized that Hsp90 is crucial in promoting the stability of 
hyperphosphorylated Akt by preventing it from being targeted for degradation. 
 
Hsp90 is reported to associate with oncogenic ‘client’ proteins that include 
kinases such as Akt, or Raf-1 and prevents its substrates from undergoing 
proteosomal degradation160. Moreover, the chaperoning activity of Hsp90 has 
been proven to be imperative for stabilizing Akt activation in vivo167. Our 
findings demonstrated that GM-induced degradation of Akt was more drastic 
in in MEFPTEN-/- as compared to wildtype cells. This further supports the notion 
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that Akt stability is highly dependent on Hsp90 in   MEFPTEN-/- as compared to 
wildtype cells. Consistent with other reports, we also showed that, GM-
induced inhibiton of Hsp90, targets Akt for proteasome mediated 
degradation251. 
 
4.2.5 Hsp90 recruitment to the membrane is dependent on Akt in 
MEFPTEN-/- cells 
 
Apart from its chaperone function, Hsp90 may be involved in intracellular 
trafficking of its client proteins252. For instance, authors have proposed that the 
Src family of kinases may be escorted by Hsp90 from the cytosol to the 
membranes252-254. Furthermore, Schulte et al.255, have reported the 
translocation of Raf-1 kinase from the cytosol to the membrane appeared to 
be dependent on Hsp90255. Sanchez et al.256, demonstrated that flavanol (-)-
Epicatechin (EPI) promotes the formation of eNOS, Akt, and Hsp90 complex 
at the caveolar membrane in human endothelial cells grown in Ca2+ deprived 
media. However, although they showed that the partial Akt/Hsp90 migration 
from the cytosol to the caveolar membrane fraction, the mechanism by which 
Hsp90 was recruited to the membrane still remains elusive256.  
 
In the current study, we postulated that the existence of Akt-Hsp90 complex 
may render pathophysiological significance in MEFPTEN-/- cells as compared to 
its wildtype counterpart. In particular, we speculated that Akt-Hsp90 may 
translocate as a complex from the cytosol to the plasma membrane in 
MEFPTEN-/- cells. Moreover, the translocation of Hsp90 from the cytosol to the 
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membrane appeared to be dependent on Akt. Further validation involving 
depletion and subsequent replenishment of membrane Akt may provide more 
insight on the functional role of Akt in recruiting more Hsp90 to the membrane 
in MEFPTEN-/- cells. 
 
4.2.6 Hsp90-Akt complex stabilizes NHE1 at the plasma membrane in 
MEFPTEN-/- cells 
 
The scaffolding function of the C-terminal cytosolic domain on NHE1 has been 
well documented, particularly its role in the assembly of signalling 
complexes257. For instance, NHE1 interacting proteins such as CHP, CaM, 14-
3-3, PIP2 bind to the cytoplasmic tail of NHE1 to influence its activity and its 
localization51,194,258. Thus, NHE1 interaction with various signalling proteins 
often results in the regulation of diverse functions of NHE1.  On the other 
hand, we have previously mentioned that NHE1 interaction with CHP1 and 3 
has been shown to affects its maturation and stability. However, the stability of 
NHE1 in a tumourigenic enviroment remains unexplored.  
 
Redlak et al.259, established that the inhibition of Akt-Hsp90 complex is crucial 
in sensitizing gastric cancer cells to the pro-apoptotic effects of 
deoxycholate259. This strongly suggests the significance of Akt-Hsp90 
complex in enhancing PI3K/Akt pathway and promoting cell survival. Indeed, a 
similar study by Zhang and colleagues260, have reported that Hsp90-Akt 
complex binding to the pro-apoptotic protein ASK1 confers protection to 
endothelial cells from stress-induced apoptosis through an inactivating 
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phosphorylation of ASK1260. Thus, these studies were directed towards the 
role of Hsp90-Akt complex in cell survival.  
 
In the current study, we postulated another role for Hsp90-Akt, whereby it may 
be involved in forming a stable complex with NHE1 at the plasma membrane 
that aids NHE1 to acquire increased stability in MEFPTEN-/- cells. Firstly, the 
destabilization of the complex through knockdown of either Hsp90 or Akt 
resulted in lesser amounts of NHE1-Akt-Hsp90 complex in MEFPTEN-/- cells. 
Secondly, API-1 mediated prevention of Akt membrane recruitment drastically 
reduced both the expression of Hsp90 and NHE1 levels at the membrane. 
Thirdly, inhibition of Hsp90 and de novo synthesis of proteins (CHX) led to the 
downregulation of both Akt and Hsp90 and thereby promoted the significant 
decrease in NHE1 protein expression. In totality, we reason that it may be 
likely that the destabilization of NHE1 may be induced through the prevention 
of Hsp90-Akt complex from being recruited to the membrane. Taken together, 
we propose that in normal conditions, the basal level of NHE1-Hsp90 detected 
in wildtype cells may be transient. However, it may be likely that Akt direct 
binding to NHE1 keeps Hsp90 at close proximity to NHE1, allowing the 
chaperone to confer stability to NHE1 in MEFPTEN-/- cells.  Moreover, it is 
possible that the scaffolding function of NHE1 induces a forced proximity 
between Hsp90 and Akt, facilitating increased stability of NHE1.  
 
Also, our work proposes another facet of Akt-Hsp90 complex in promoting cell 
survival through NHE1 in MEFPTEN-/- cells. In recent years, studies have 
highlighted the role of NHE1 in tumour cell survival193. A key observation 
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made when GM-induced MEFPTEN-/- cells displayed enhanced sensitivity to cell 
death in comparison to wild-type cells. We reasoned that this could be the 
cumulative effect of the down-regulation of both Akt and Hsp90, destabilizing 
NHE1 protein expression. Since, Hsp90–Akt complex has been implicated in 
cell survival259,260, our findings propose that the NHE1-Akt-Hsp90 complex 
may be another possible mechanism by in cell survival. Further investigation 
assessing the impact of Hsp90-Akt on NHE1 in cell survival may be crucial in 
















4.3 Physiological relevance of novel NHE1-Akt-Hsp90 complex in 
MCF10AT1kcl.2 breast cancer series  
 
4.3.1 Detection of novel Hsp90-Akt-NHE1 complex in malignant 
MCF10CA1a breast epithelial cells  
 
NHE1 has been reported to play a crucial role in the malignant progression of 
cancer261. Indeed, past studies have established that several factors that 
include hypoxia, increased glycolysis and low serum content may elevate 
NHE1 expression levels62. Moreover, the increased NHE1 protein levels may 
contribute towards the malignant transformation of cells173,174. For instance, 
past studies show a strong correlation between NHE1 expression and the 
severity of liver cancer progression52,53. In fact, a group study conducted in 
patients with hepatocellular carcinoma showed that enhanced NHE1 
expression correlated with both increased tumour size and increased 
mortality262,263. Consistent with these reports, in our study, we found that 
NHE1 protein expression has been shown to be modulated at different stages 
in cancer depicted in the MCF10AT1kcl.2 series of breast epithelial cell lines. 
In particular, NHE1 protein expression levels were enhanced in the pre-
malignant 10AT1 and malignant CA1a cells as compared to the benign 10A1 
cells. This indicates a possibility that elevated NHE1 protein expression might 
accompany tumor progression from early stages. In contrast to this 
observation, we found that the malignant CA1h, derived from the same 
xenograft source of CA1a, showed the least expression of NHE1 levels across 
the MCF10AT1kcl.2 breast cancer series. Although we have not explored 
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much into the regulation of NHE1 expression in CA1h, we reasoned that the 
decline in expression of NHE1 observed may be due to decreased 
transcription rates of the NHE1 gene or from increased degradation of the 
protein itself.  
 
Studies conducted in stress-induced human renal proximal tubule epithelial 
cells highlight the link between the PI3K pathway and NHE1-ERM complex in 
cell survival74. Interestingly, several studies have addressed the importance of 
NHE1 scaffolding activity in tumourigenesis264,265. Magalhaes et al.264, 
demonstrated that pH-induced cortactin phosphorylation promoted the 
recruitment of NHE1-ERM complex to invadopodia, potentiating metastasis in 
MDA-MB-231 breast cancer cells. Furthermore, the regulation of NHE1 
activity has been shown to involve the PI3K pathway in normal mammary cells 
and breast cancer cells266,267. However, the role of NHE1 and Akt working 
together in tumourigenesis, remains to be explored.  
 
We have established that Hsp90-Akt complex is imperative in regulating the 
stability of NHE1 in MEFPTEN−/− cells, we next asked if this novel tripartite 
complex is physiologically relevant in a tumourigenic environment. Upon 
screening the MCF10AT1kcl.2 series of cell lines that incur different degrees 
of malignancy268,269, our findings suggest several factors that purport the 
congruence between MEFPTEN−/− cells and CA1a breast epithelial cells. Firstly, 
CA1a inherits similar characteristics such as hyperphosphorylation of Akt202 
and increased expression of NHE1 as compared to 10A1 non-tumourigenic 
cells. Secondly, abrogation of Akt function using LY294002 and specific Akt 
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siRNA yielded a drastic decrease in NHE1 protein expression in CA1a cells. 
Thirdly, the detection of the tripartite NHE1-Akt-Hsp90 complex in CA1a cells 
suggests that the Akt-Hsp90 complex is most likely to be imperative for the 
physiological stability of NHE1 protein. These observations show that Akt may 
be involved in the regulation of NHE1 expression, as observed in MEFPTEN−/− 
cells. Another pertinent finding in our study is that inhibition of Hsp90 function 
significantly blunted NHE1 levels. Thus we proposed that the stability of NHE1 
may be positively regulated through the physical interaction of Hsp90-Akt. 
 
Previous studies have demonstrated that Hsp90 expression in tumourigenic 
cells to be crucial in the survival and growth of cancer cells239. Indeed, Hsp90 
has been implicated in the regulation of the oncogenic client protein, Akt. 
Thus, we postulated that Hsp90 may exist in CA1a for the need of stabilizing 
the prosurvival kinase Akt. Using immunoprecipitation studies, we 
demonstrated that Akt appears to be dependent on Hsp90 in CA1a cells in 
comparison to other cell lines within the MCF10AT1kcl.2 series. Through this 
observation, we postulate that it is likely that Akt may be involved in the 
recruitment of Hsp90 to the plasma membrane, similar to MEFPTEN−/− cells.  
 
In the time-course study of CHX- mediated inhibition of protein synthesis, we 
found that CA1a cells displayed prolonged stability of NHE1 expression as 
compared to non-tumourigenic 10A1 cells. Consistent with the findings in 
MEFPTEN−/− cells, it is likely that Hsp90-Akt complex may be enhancing the 
stability of NHE1 at the plasma membrane through direct physical interaction. 
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Although it is unlikely that Hsp90-Akt interaction with NHE1 affects its activity 
in CA1a cells, further experiments are needed to prove this.  
 
4.3.2 The stability of Akt may play a role in the transition between pre-
malignant MCF10AT1 to malignant MCF10CA1a breast epithelial cells  
 
mTORC2- mediated phosphorylation at the Thr450-Pro site of Akt has been 
shown to control protein folding, maturation and stability270. Interestingly, 
Facchinetti et al.271, demonstrated that the lack of Thr450 phosphorylation in 
cells, were rescued by the interaction between Akt and Hsp90. Thus, another 
level of protection is conferred through the Hsp90 chaperone which has been 
shown to rescue Akt from PP2A -induced degradation167. Hence, the stability 
of Akt is imperative in the mechanistic activation of its downstream targets 
involved in various cellular processes. Interestingly, Akt has been reported to 
be crucial in the oncogenic transformation of signalling pathways272. 
 
In the current study, we show that the stability of Akt is a crucial factor in 
driving cancer progression. Taking into account that the inability to detect 
phosphorylated Akt or total Akt by western blots, we reasoned that this is due 
to the high turnover of Akt that exist in this cell line or transcription of Akt is 
low. As expected, immunoprecipitated NHE1 was also unable to pull down 
detectable amounts of Akt visible by western blot. Interestingly, our studies 
evidently show MG132 stabilized Akt and this action was able to promote the 
formation of the tripartite complex, Hsp90-Akt-NHE1 in 10AT1 cell line, 
mimicking the similar phenomenon detected in CA1a malignant cells. Thus, 
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we propose that Akt stability may be crucial in driving transformation from pre-
malignant to a more malignant state.  In light of our results, our data was 
suggestive that Akt stability may play a role in cancer progression. However, 
























4.4. Regulation of Akt Ser 473 phosphorylation by NHE1 in both  
MEFPTEN-/- cells and MCF10CA1a breast epithelial cells  
 
4.4.1 NHE1 scaffolding function promotes the regulation of Akt Ser 473 
phosphorylation in both MEFPTEN-/- cells and MCF10CA1a breast 
epithelial cells  
 
The mTORC2 complex which comprises of mTOR, mLST8, Rictor and the 
stress activated protein kinase-interacting protein (Sin1) is instrumental in 
regulating the phosphorylation of Akt at the Ser 473 site273,274. However, 
deletion of Rictor, mLST8 or SIN1 components of the mTORC2 complex leads 
to inhibtion of Akt phosphorylation at the Ser473 site275-277. Moreover, apart 
from mTOR, Rictor also assists in the recruitment of other substrates on to the 
mTORC2 complex275,278. Although previous studies have proposed that mTOR 
may be involved in the regulation of NHE1 activity in epithelial function, their 
work showed that mTOR appeared to be downstream of PI3K, indicative of 
the mTORC1 complex279. 
 
In the present study, we hypothesized that the mTORC2 complex which 
directs Akt phosphorylation at the Ser 473 site, may have an effect on NHE1 
protein expression directly. Past work showed that amiloride-mediated 
inhibition of NHE1 function, was found to enhance TRAIL-induced apoptosis 
through inhibition of Akt phosphorylation in tumour cells such as HeLa and 
LNCaP280. In agreement with previous reports, we have also observed that 
abrogation of NHE1, dephosphorylated Akt at the Serine 473 site in 
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MEFPTEN−/− (Appendix B). In addition, in the current investigation, we found 
that silencing of Hsp90 downregulated Akt phosphorylation at the Ser 473 site  
and  NHE1 expression concurrently in both MEFPTEN−/− cells and CA1a. 
Together, these findings purport the fact that NHE1 may be linked to the 
mTORC2 complex.  
 
Interestingly, our study showed that subcellular fractionation in both 
MEFPTEN−/− cells and CA1a cells detected mTOR and Rictor accumulation in 
the plasma membrane. These observations were in line with previous studies 
whereby a small amount of mTOR and rictor was found enriched in the 
plasma membrane, although the endoplasmic reticulum has been identified as 
main localization site for mTORC2 complex281. Also, immunoprecipitated 
NHE1 was found to interact with mTOR and Rictor in two different cell lines, 
MEFPTEN−/− cells and CA1a. Based on our findings, it is conceivable that 
mTOR/Rictor bound to NHE1 may influence the amplification of Akt activation 
detected in MEFPTEN−/− cells and CA1a.  
 
NHE1 plays a significant role as a scaffolding platform for multiple protein 
kinases257. Thus, it is likely that NHE1 may act as an anchor for mTORC2 
complex to amplify Akt phosphorylation at the plasma membrane in 
MEFPTEN−/− cells and CA1a. The full activation of Akt at the membrane is 
dependent on both mTORC2 complex and PDK1. Thus, it is necessary for 
these upstream kinases to be brought in close proximity to Akt for its 
activation. We have previously established a correlation between Akt and 
NHE1. Together, we postulate that NHE1 may act as a scaffolding platform for 
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both mTORC2 and Akt. We propose that NHE1- mTORC2 interaction may be 
involved in amplifying the Akt phosphorylation at the Ser 473 site observed in 
both in MEFPTEN−/− cells and CA1a. This may also add to the 
hyperphosphorylation status of Akt detected in both MEFPTEN−/− cells and 
CA1a cell lines. Hence, the possibility of feedback loop may exist between 
mTORC2, Akt, Hsp90 and NHE1 regulation that may be relevant in tumour 






















In summary, our study highlights an unappreciated role for the molecular 
chaperone, Hsp90 in the regulation of proteins that are involved in ion 
homeostasis. We propose that NHE1 may be a potential client protein of 
Hsp90 as our data demonstrated that the increased stability of NHE1 protein 
expression observed in in MEFPTEN-/- cells is regulated through its interaction 
with the chaperone Hsp90, a phenomenon absent in its wildtype fibroblasts. 
Additionally, we also showed that Hsp90 not only protects NHE1 from 
degradation but also may be involved in preventing the ubiquitination of NHE1 
in MEFPTEN-/- cells.  
 
Another pertinent finding in our study is that rather than its activity, the 
membrane recruitment of Akt appeared crucial in the regulation of NHE1 
protein expression. Moreover, we further demonstrated that Akt mediated 
regulation of NHE1 protein in MEFPTEN-/- cells is transcription independent. 
Further analysis suggests an unconventional role for Akt, whereby it is 
involved in the recruitment of the cytosolic Hsp90 to the plasma membrane in 
MEF PTEN-/- cells. Our study demonstrated that Hsp90–Akt complex was 
imperative in the regulation of NHE1 protein stability in MEFPTEN-/- cells. 
Although NHE1 acts as an anchor for both Hsp90 and Akt, its exchanger 
activity appears to be independent of its scaffolding mechanism in MEFPTEN-/- 
cells. Thus, we propose that the formation of the tripartite NHE1-Akt-Hsp90 
complex detected in MEFPTEN-/- cells may be relevant in the sustenance of 




To further stress the physiological relevance of our finding, we discovered that 
the tripartite Hsp90-Akt-NHE1 complex was detectable in the malignant CA1a 
breast cancer cell line, mimicking our observation in MEFPTEN-/- cells. This 
finding adds weight to our hypothesis, such that in certain malignant cancer 
cell lines that incur hyperphosphorylation of Akt and increased NHE1 
expression, it is highly possible that Hsp90-Akt complex may be involved in 
the stability of NHE1 expression.  
 
Also, our studies pinpoint towards the importance of the stability of Akt that is 
imperative in the transition of premalignant cells (10AT1) to metastatic (CA1a) 
during the course of tumorigenesis. Since NHE1 has strong implications in 
tumour cell survival, the asssociation of Hsp90, Akt, and NHE1 may highly 
likely co-operatively and synergistically promote tumour cell survival or even 
cancer progression. Thus, we show for the first time that the novel tripartite 
Hsp90-Akt-NHE1 complex may act as a possible ‘molecular signature’ 
complex that may be a potential marker for cancer progression. Hence, further 
understanding of this complex may give insight into the therapeutic 
approaches for treatment of tumor cells. 
 
Lastly, we showed that NHE1 may serve as a platform for the recruitment of 
mTOR and Rictor in both MEFPTEN-/- and CA1a cell line. This in turn, may allow 
the amplification of Akt phosphorylation at the Ser 473 site. Thus, our data 
suggest that a feedback loop may exist, involving Hsp90, Akt and NHE1 and 
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the mTOR2 complex. A schematic representation of a summary of our 




Figure 52: Summary of the key findings in this project 
 
At a basal level, the NHE1 forms complex with Hsp90 and Akt independently. 
Hsp90 interaction with NHE1 also prevents the ubiquitination of NHE1 and 
Akt. In MEFPTEN-/- cells and MCF10CA1a cells, Akt forms a complex with 
Hsp90 and translocates from the cytosol to the membrane and increases the 
stability of NHE1 at the membrane. mTOR/Rictor bound to NHE1 regulates 
amplifies the phosphorylation of Akt at the Ser 473 site. This represents a 
feedback loop that may be crucial in the regulation of NHE1 stability and cell 
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Appendix A: NHE1 expression but not activity is involved in regulation 
of Akt Phosphorylation  
 
(A) MEFPTEN-/- cells were treated with different doses of EIPA or cariporide for 
24 hrs prior to measurement of NHE activity. (B) MEFPTEN-/- cells were treated 
with different doses of EIPA or cariporide (Cari) for 24 hrs prior to immunoblot. 
A representative blot from two independent experiments is shown. (Adapted 




Appendix B. Effect of silencing NHE1 leads to Akt dephosphorylation. 
 
MEFPTEN-/- cells (KO) were transfected with NHE1 siRNA (siNHE1) or control 
siRNA (sico). Twenty four hours post transfection, cells were serum-deprived 
in DMEM/0.5%FBS (KO 0.5%) for another 24 hrs or grown in DMEM/10%FBS 
(KO 10%). 48 hours post transfection, cell lysates were subjected to 
immunoblot blot analysis. A representative blot from three independent 
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